CN111701010A - 用色氨酸或酪氨酸稳定的液体神经毒素制剂 - Google Patents

用色氨酸或酪氨酸稳定的液体神经毒素制剂 Download PDF

Info

Publication number
CN111701010A
CN111701010A CN202010742639.2A CN202010742639A CN111701010A CN 111701010 A CN111701010 A CN 111701010A CN 202010742639 A CN202010742639 A CN 202010742639A CN 111701010 A CN111701010 A CN 111701010A
Authority
CN
China
Prior art keywords
asn
ile
leu
lys
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010742639.2A
Other languages
English (en)
Other versions
CN111701010B (zh
Inventor
A·亚尔斯塔德
A·弗里斯
U·斯特尔
A·古雷尔
B·阿格伦
E·埃德斯特隆
A·皮克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Priority to CN202010742639.2A priority Critical patent/CN111701010B/zh
Publication of CN111701010A publication Critical patent/CN111701010A/zh
Application granted granted Critical
Publication of CN111701010B publication Critical patent/CN111701010B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20Halogens; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24Phosphorous; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39Derivatives containing from 2 to 10 oxyalkylene groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/06Preparations for care of the skin for countering cellulitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30Characterized by the absence of a particular group of ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及不含动物蛋白质的稳定液体神经毒素制剂,其包含表面活性剂,选自色氨酸和酪氨酸的氨基酸,包含钠、氯和磷酸根离子的缓冲剂,其pH值在5.5和8之间,并且其稳定2个月。这些组合物适用于治疗,特别是用于施用给患者以获得所需的治疗或审美效果。本发明还涉及选自色氨酸和酪氨酸的氨基酸用于保护蛋白质性神经毒素免于在不含动物来源的蛋白质的液体组合物中降解的用途。

Description

用色氨酸或酪氨酸稳定的液体神经毒素制剂
本申请为申请号为2017800445651,申请日为2017年5月26日,发明名称为“用色氨酸或酪氨酸稳定的液体神经毒素制剂”的分案申请。
技术领域
本发明涉及无动物蛋白质的液体神经毒素制剂。特别地,本发明涉及用非蛋白质赋形剂稳定的无动物蛋白质的液体肉毒杆菌神经毒素制剂。
本文所述的神经毒素制剂适用于治疗,特别是施用给患者以达到所需的治疗或审美效果(aesthetic effect)。
背景技术
由梭菌菌株天然产生的梭菌神经毒素是迄今已知的毒性最大的生物剂,同时是治疗许多神经肌肉和内分泌疾病的有力工具,包括颈肌张力障碍、痉挛、眼睑痉挛、多汗症或流涎。它们还在审美领域中用于抚平皱纹。
为了适合用作药物产品,神经毒素组合物必须能够储存而不会显著丧失神经毒素活性。
在目前批准的所有肉毒神经毒素制剂中,动物(包括人)蛋白质,通常是人血清白蛋白(HSA),用作稳定剂。
然而,药物组合物中动物蛋白质如HSA的存在是不希望的,这归因于非意愿地将动物源性传染物如朊病毒传播给患者的风险,即使这种风险低。
本领域已经公开了不含动物蛋白质的肉毒杆菌毒素制剂。例如,WO0158472描述了冻干组合物,其中多糖如2-羟乙基淀粉用于稳定肉毒杆菌毒素。WO2005007185描述了组合物,其中表面活性物质和选自Glu和Gln或Asp和Asn的至少两种氨基酸的混合物用于稳定肉毒杆菌毒素。
然而,大多数现有技术的制剂在液体形式时是不稳定的,并因此以冻干或冷冻干燥的形式储存。在施予患者之前,医师需要将这些制剂重建于无菌盐水溶液中。该重建步骤造成医生的时间损失、稀释错误的风险以及重构过程中的污染风险。肉毒杆菌毒素提供者还必须培训医生,以确保重建步骤得到恰当执行。
因此,液体制剂是有利的,因为它们避免了医生的时间损失、稀释错误的风险、污染风险并且无需为提供者提供培训。
例如在WO 2006005910中描述了不含HSA的液体制剂,其公开了包含表面活性剂、氯化钠和二糖的液体肉毒杆菌毒素制剂。WO2009008595公开了包含聚山梨醇酯20和甲硫氨酸的液体肉毒杆菌毒素制剂。
本发明的目的是提供有利的无动物蛋白质的肉毒杆菌神经毒素液体制剂,其适于储存和用于治疗。特别地,稳定制剂应该保持产品稳定性,不含动物蛋白质,并且还适合于稳定不含复合蛋白质的神经毒素。
发明内容
本发明的第一方面是一种液体组合物,其包含蛋白质性神经毒素,表面活性剂,选自色氨酸和酪氨酸的氨基酸,包含钠、氯和磷酸根离子的缓冲液,或基本上由其组成,其pH值在5.5和8之间,其随时间稳定且其不含动物来源的蛋白质。
另一方面是本发明的液体组合物在治疗和/或美容中的用途。
本发明的另一方面是选自色氨酸和酪氨酸的氨基酸用于保护蛋白质性神经毒素免于在不含动物来源的蛋白质的液体组合物中降解的用途。
具体实施方式
本发明的第一方面是液体组合物,其包含蛋白质性神经毒素,表面活性剂,选自色氨酸和酪氨酸的氨基酸,包含钠、氯和磷酸根离子的缓冲液,或基本上由其组成,其pH值在5.5和8之间,其随时间稳定且其不含动物来源的蛋白质。
“不含动物蛋白”应理解为不包含动物包括人来源的蛋白。
神经毒素是一类靶向神经细胞并影响神经功能的物质。蛋白质性神经毒素包括肉毒杆菌毒素(BoNT)和破伤风毒素(TeNT)。优选地,蛋白质性神经毒素是肉毒杆菌神经毒素。
肉毒杆菌神经毒素是150kDa金属蛋白酶,其由通过二硫桥连接的活性形式的50kDa轻链(L)和100kDa重链(H)组成。L链是锌-蛋白酶,其在细胞内切割参与囊泡介导的神经递质释放的SNARE(可溶性NSF附着蛋白受体)蛋白之一,从而破坏神经递质介导的机制。重链包括两个结构域:N端50kDa易位结构域(HN)和C端50kDa受体结合结构域(HC)。肉毒杆菌神经毒素的HC结构域包含两个不同的结构特征,称为HCC和HCN结构域。据信参与受体结合的氨基酸残基主要位于HCC结构域中。
肉毒杆菌神经毒素已被分类为7种抗原性不同的血清型(A至G)。每种血清型的示例性氨基酸序列在本文中为SEQ ID NO 1至7。
对于每个序列,不同的结构域可以例如如下所示。
血清型 L链 H<sub>N</sub>结构域 H<sub>CN</sub>结构域 H<sub>CC</sub>结构域
BoNT/A(SEQ ID NO 1) 1-448 449-871 872-1110 1111-1296
BoNT/B(SEQ ID NO 2) 1-440 441-858 859-1097 1098-1291
BoNT/C(SEQ ID NO 3) 1-441 442-866 867-1111 1112-1291
BoNT/D(SEQ ID NO 4) 1-445 446-862 863-1098 1099-1276
BoNT/E(SEQ ID NO 5) 1-422 423-845 846-1085 1086-1252
BoNT/F(SEQ ID NO 6) 1-439 440-864 865-1105 1106-1274
BoNT/G(SEQ ID NO 7) 1-441 442-863 864-1105 1106-1297
技术人员理解,每个肉毒杆菌神经毒素结构域中均可以存在一些变化。
例如,BoNT通过阻止乙酰胆碱的释放从而防止肌肉收缩而作用于神经肌肉神经连接。神经末梢中毒是可逆的,且其持续时间因不同的BoNT血清型而异。
天然BoNT由肉毒杆菌(Clostridium botulinum)和其他梭菌属物种如酪酸杆菌(C.butyricum)、巴氏梭菌(C.baratii)和阿根廷梭菌(C.argentinense)产生,作为保护神经毒素免于蛋白水解降解的多蛋白复合物的一部分。“复合物形式的肉毒杆菌神经毒素”是指肉毒杆菌神经毒素和在性质上属于这类多蛋白质复合物的部分的一种或多种蛋白质(神经毒素相关蛋白质或“NAP”)。NAP包括无毒的非血凝素(NTNH)蛋白和血凝素蛋白(HA-17、HA-33和HA-70)。“高纯度肉毒杆菌神经毒素”是指基本上不含NAP的肉毒杆菌神经毒素。
根据本发明的一个实施方案,肉毒杆菌神经毒素是复合物形式的肉毒杆菌神经毒素。根据另一个实施方案,肉毒杆菌神经毒素是高纯度的肉毒杆菌神经毒素。
通过培养天然梭菌菌株生产BoNT并以复合物形式或高纯度形式纯化它们的方法是本领域熟知的,并且描述于例如Pickett,Andy."Botulinum toxin as a clinicalproduct:manufacture and pharmacology."Clinical Applications of BotulinumNeurotoxin.Springer New York,2014.7-49。
高纯度或基本上纯的肉毒杆菌神经毒素可以从包含肉毒杆菌毒素的蛋白质复合物中获得,例如根据Current Topics in Microbiology and Immunology(1995),195,p.151-154中描述的方法。
或者,可以通过在异源宿主如大肠杆菌中重组表达BoNT基因并从中纯化来产生高纯度肉毒杆菌神经毒素。
优选地,蛋白质性神经毒素是肉毒杆菌神经毒素。根据本发明的一个实施方案,肉毒杆菌神经毒素是复合物形式的肉毒杆菌神经毒素。根据另一个实施方案,肉毒杆菌神经毒素是高纯度的肉毒杆菌神经毒素。
根据本发明的一个实施方案,肉毒杆菌神经毒素是从其天然梭菌菌株纯化的肉毒杆菌神经毒素。根据另一个实施方案,肉毒杆菌神经毒素是在异源宿主如大肠杆菌中重组产生的肉毒杆菌神经毒素。
根据本发明,肉毒杆菌神经毒素可以是血清型A、B、C、D、E、F或G的BoNT。
根据本发明,肉毒杆菌神经毒素可以是修饰的肉毒杆菌神经毒素。根据本发明,“修饰的BoNT”是具有与SEQ ID NO 1、2、3、4、5、6或7具有至少50%序列同一性的氨基酸序列的BoNT。优选地,修饰的BoNT具有与SEQ ID NO 1、2、3、4、5、6或7具有至少60%、70%、80%、85%、90%、95%、96%、97%、98%或99%序列同一性的氨基酸序列。优选地,修饰的BoNT是如下所述的BoNT:其氨基酸序列与SEQ ID NO 1、2、3、4、5、6或7相差小于600、400、200、150、100、50或20个氨基酸取代、缺失或添加,例如10、9、8、7、6、5、4、3、2或1个氨基酸取代、缺失或添加。
根据本发明,重组肉毒杆菌神经毒素可以是嵌合肉毒杆菌神经毒素。根据本发明,“嵌合BoNT”由不全属于同一血清型的L、HN、HCN和HCC结构域构成。例如,嵌合BoNT可以由来自一种血清型的L链和来自不同血清型的完整H链(HN、HCN和HCC结构域)组成。嵌合BoNT还可以由来自一种血清型的L链和HN结构域(“LHN”)和来自不同血清型的HC结构域(HCN和HCC)组成。嵌合BoNT还可以由来自一种血清型的L链和HN和HCN结构域(“延伸的LHN”)和来自不同血清型的HCC结构域组成。
根据本发明,轻链结构域(L)可具有与下列氨基酸序列之一具有至少50%,优选至少60%、70%、80%、90%或95%序列同一性且保留切割参与囊泡介导的神经递质释放的SNARE蛋白之一的能力的氨基酸序列:
·SEQ ID NO:1的氨基酸1-448
·SEQ ID NO:2的氨基酸1-440
·SEQ ID NO:3的氨基酸1-441
·SEQ ID NO:4的氨基酸1-445
·SEQ ID NO:5的氨基酸1-422
·SEQ ID NO:6的氨基酸1-439
·SEQ ID NO:7的氨基酸1-441
根据本发明,HN结构域可具有与下列氨基酸序列之一具有至少50%,优选至少60%、70%、80%、90%或95%序列同一性且保留易位能力的氨基酸序列:
·SEQ ID NO:1的氨基酸449-871
·SEQ ID NO:2的氨基酸441-858
·SEQ ID NO:3的氨基酸442-866
·SEQ ID NO:4的氨基酸446-862
·SEQ ID NO:5的氨基酸423-845
·SEQ ID NO:6的氨基酸440-864
·SEQ ID NO:7的氨基酸442-863
根据本发明,HC结构域可具有与下列氨基酸序列之一具有至少50%,优选至少60%、70%、80%、90%或95%序列同一性且保留结合神经肌肉细胞的能力的氨基酸序列:
·SEQ ID NO:1的氨基酸872-1296
·SEQ ID NO:2的氨基酸859-1291
·SEQ ID NO:3的氨基酸867-1291
·SEQ ID NO:4的氨基酸863-1276
·SEQ ID NO:5的氨基酸846-1252
·SEQ ID NO:6的氨基酸865-1274
·SEQ ID NO:7的氨基酸864-1297
根据本发明,HCC结构域可具有与以下氨基酸序列之一具有至少50%,优选至少60%、70%、80%、90%或95%序列同一性且保留结合神经肌肉细胞的能力的氨基酸序列:
·SEQ ID NO:1的氨基酸1111-1296
·SEQ ID NO:2的氨基酸1098-1291
·SEQ ID NO:3的氨基酸1112-1291
·SEQ ID NO:4的氨基酸1099-1276
·SEQ ID NO:5的氨基酸1086-1252
·SEQ ID NO:6的氨基酸1106-1274
·SEQ ID NO:7的氨基酸1106-1297
上述参考序列应被视为指导,因为根据亚血清型可能发生轻微变化。
两个或更多个核酸或氨基酸序列之间的“百分比序列同一性”是所比对的序列享有的相同位置处的相同核苷酸/氨基酸数量的函数。因此,%同一性可以计算为比对中每个位置的相同核苷酸/氨基酸的数量除以比对的序列中核苷酸/氨基酸的总数乘以100。%序列同一性的计算还可能考虑空位的数量,以及需要引入以优化两个或更多个序列的比对的每个空位的长度。序列比较和两个或多个序列之间的百分比同一性的确定可以通过使用特定的数学算法进行,例如BLAST,这是技术人员熟悉的。
表面活性剂是能够降低液体和固体之间或两种液体之间的表面张力的化合物。表面活性剂可以是非离子的、阴离子的、阳离子的或两性的。在本发明的组合物中,表面活性剂优选是非离子表面活性剂。非离子表面活性剂包括聚氧乙二醇烷基醚,如八乙二醇单十二醚或五乙二醇单十二醚;聚氧丙二醇烷基醚;葡糖苷烷基醚,如癸基葡糖苷、月桂基葡糖苷或辛基葡糖苷;聚氧乙二醇辛基酚醚,如Triton X-100;聚氧乙二醇烷基酚醚,如Nonoxynol-9;甘油烷基酯,如月桂酸甘油酯;聚氧乙二醇脱水山梨糖醇烷基酯,如聚山梨醇酯;脱水山梨糖醇烷基酯,如司盘类;椰油酰胺MEA,椰油酰胺DEA;十二烷基二甲胺;聚乙二醇和聚丙二醇的嵌段共聚物,如泊洛沙姆;聚乙氧基化牛脂胺(POEA)。
根据优选的实施方案,本发明的液体组合物包含非离子表面活性剂,其为聚山梨醇酯(polysorbate),优选聚山梨醇酯20(PS20)、聚山梨醇酯60(PS60)或聚山梨醇酯80(PS80)。最优选地,非离子表面活性剂是PS80。当表面活性剂是聚山梨醇酯时,其浓度优选为0.001%至15%v/v,更优选0.005至2%v/v,更优选0.01至1%,例如0.01、0.05、0.1、0.2、0.5或1%v/v。根据一个实施方案,表面活性剂为PS80,浓度为0.05至0.2%v/v,例如约0.05、0.06、0.07、0.08、0.09、0.10、0.11、0.12、0.13、0.14、0.15、0.16、0.17、0.18、0.19或0.20%v/v。
PS20的密度约为1.1g/mL。PS60的密度约为1.044g/mL。PS80的密度为约1.06至1.09g/mL。
聚山梨醇酯被认为形成胶束并防止蛋白质吸附到表面和蛋白质聚集。不希望受理论束缚,认为在降解/氧化时,聚山梨醇酯可形成可能对蛋白质稳定性具有影响的过氧化物和酸。因此,认为优选聚山梨醇酯的浓度在产品配方中尽可能低。因此,认为优选聚山梨醇酯的浓度不应超过其临界胶束浓度(CMC)的200倍,更优选其不应超过其CMC的100、50、20、10或5倍。
对于PS20(Mw 1227.5g/mol),CMC在21℃下近似为8×10-5M,即约0.01%w/v。
对于PS60(Mw 1309g/mol),CMC在21℃下约为21×10-6M,即约0.003%w/v。
对于PS80(Mw 1310g/mol),CMC在21℃下近似为12×10-6M,即约0.002%w/v。
根据优选的实施方案,聚山梨醇酯浓度在给定温度下为其CMC的1至200倍,例如约21℃,优选其CMC的2至100倍,例如其CMC的约20或50倍。
本发明的液体组合物包含氨基酸色氨酸或酪氨酸。不希望受理论束缚,推测色氨酸或酪氨酸可以防止活性蛋白质的氧化,所述氧化将使其无功能。实际上,认为相对于神经毒素以摩尔过量添加的氨基酸首先被氧化,从而挽救神经毒素。还推测色氨酸或酪氨酸可以中和表面活性剂如聚山梨醇酯的反应性降解产物。
优选地,氨基酸是色氨酸。更优选地,氨基酸是L-色氨酸。
氨基酸浓度优选为约0.1至5mg/mL,更优选0.1至5mg/mL、0.25至3mg/mL,例如约0.25、0.5、1、1.5、2或3mg/mL。
本发明的组合物包含缓冲剂,其包含钠、氯和磷酸根离子。发明人确实惊奇地发现,没有钠、氯离子和磷酸根离子的缓冲剂降低了毒素的稳定性。优选地,缓冲剂还包含钾离子。
缓冲剂可以例如通过组合氯化钠、氯化钾和磷酸钠盐来获得。氯化钠浓度优选为10至500mM,优选约25至300mM,例如约25、50、75、100、140、150、200、250或300mM。
磷酸钠浓度优选为1至100mM,优选为2至50mM,例如约2、5、10、20、30、40或50mM。
氯化钾浓度优选为1至50mM,优选1至10mM,例如约1、2、3、4、5或10mM。
本发明的组合物具有5.5至8的pH。根据优选的实施方案,pH为6.0-7.5,例如约6.3、6.35、6.4、6.45、6.5、6.55、6.6、6.65、6.7、6.75、6.8、6.85、6.9、6.95、7.0、7.05、7.1、7.15、7.2、7.25、7.3、7.35、7.4、7.45或7.5。优选地,pH在距生理pH(其为约7.4)的一个单位内。
本发明的组合物是液体。组合物优选包含水性稀释剂,更优选水,例如无菌水、注射用水、净化水、注射用无菌水。
优选地,该制剂是等渗的并且适合于注射给患者,特别是人类患者。
肉毒杆菌神经毒素的量通常以小鼠LD50(50致死剂量)单位表示,定义为小鼠的半数致死的腹膜内剂量。
用于肉毒杆菌毒素的小鼠LD50(MLD50)单位不是标准化单位。实际上,市售毒素的不同制造商使用的测定方法在稀释缓冲剂的选择方面尤其不同。例如,用于
Figure BDA0002607250570000091
的测试使用明胶磷酸盐缓冲液,而用于
Figure BDA0002607250570000092
的测定方法使用盐水作为稀释剂。明胶缓冲液被认为以LD50测定方法中使用的高稀释度保护毒素。相比之下,认为使用盐水作为稀释剂会导致一些效力损失。这可以解释为什么当使用
Figure BDA0002607250570000093
测定方法进行测试时,一个
Figure BDA0002607250570000094
单位等于大约三个Dysport单位(Straughan,DW,2006,ATLA 34(3),305-313;Hambleton和Pickett,Hambleton,P.和A.M.Pickett.,1994,Journal of the RoyalSociety of Medicine 87.11:719)。
优选地,用于测定小鼠LD50的稀释缓冲液是明胶磷酸盐缓冲液。例如,可以如Hambleton,P.等人,Production,purification and toxoiding of Clostridiumbotulinum type A toxin.Eds.G.E.Jr Lewis,and P.S.Angel.Academic Press,Inc.,NewYork,USA,1981,p.248所述测定小鼠LD50。简言之,将肉毒杆菌毒素样品在pH6.5的0.2%(w/v)明胶0.07M Na2HPO4缓冲液中系列稀释。将体重约20g的小鼠组(例如每组4至8只小鼠)腹膜内注射稀释的毒素样品(例如每只动物0.5ml)。选择稀释组,例如5个稀释组,以跨越50%致死剂量。观察小鼠长达96小时,并且估计小鼠50致死剂量(MLD50)。
本发明的组合物优选包含每毫升4至10000个LD50单位的肉毒杆菌神经毒素,更优选每毫升10至2000个LD50单位的肉毒杆菌神经毒素,例如每毫升20、30、40、50、75、100、200、300、400、500、600、700、800、900、1000或1500个LD50单位的肉毒杆菌神经毒素。
肉毒杆菌神经毒素的量也可以用ng表示。本发明的组合物优选包含每mL约0.01至75ng的肉毒杆菌神经毒素,更优选每mL约0.03至20ng的肉毒杆菌神经毒素,更优选每mL约0.1至15ng的肉毒杆菌神经毒素,例如约每毫升0.15、0.3、0.5、0.75、1、2、3、4、5、6、7、8、9或10ng的肉毒杆菌神经毒素。
本发明的制剂不含动物蛋白质。特别地,本发明的组合物不包含白蛋白,并且特别是不包含人血清白蛋白。优选地,本发明的组合物不含动物产品,这意味着它们不包含动物(包括人)来源的成分。优选地,本发明的组合物不包含除蛋白质性神经毒素以外的蛋白质。根据另一个实施方案,本发明的组合物不包含除蛋白质性神经毒素和一种或多种NAP(神经毒素相关蛋白)以外的蛋白质。为了避免怀疑,注意氨基酸不是蛋白质。
根据本发明的一个实施方案,组合物不包含糖类,包括不含单糖,不含二糖和不含多糖。
本发明的液体组合物随时间稳定。例如,它在2至8℃下稳定2个月。根据一个实施方案,其在2至8℃下稳定3个月,例如在5℃下。根据优选的实施方案,它在2至8℃下稳定6个月,例如在5℃下。根据一个实施方案,其在2至8℃下稳定12个月,例如在5℃下。根据一个实施方案,其在2至8℃下稳定18个月,例如在5℃下。根据一个实施方案,其在2至8℃下稳定24个月,例如在5℃下。根据一个实施方案,其在2至8℃下稳定36个月,例如在5℃下。根据一个实施方案,其在室温下稳定3个月,例如在25℃下。根据一个实施方案,其在室温下稳定6个月,例如在25℃下。根据一个实施方案,它在37℃下稳定2个月。
本发明的液体组合物优选在0°至30℃的温度下储存。在优选的实施方案中,将其储存在2-8℃,例如5℃。在另一个实施方案中,将其储存在室温下。优选地,它不是冷冻的。
可以通过比较肉毒杆菌神经毒素随时间的活性来评估稳定性。肉毒杆菌神经毒素的活性可以指肉毒杆菌神经毒素与细胞上其靶受体结合,将轻链转移到细胞中,和/或切割其靶SNARE蛋白的活性的能力。
测量肉毒杆菌神经毒素活性的方法是本领域熟知的。肉毒杆菌神经毒素活性可以例如通过使用下述方法来评估:如上所述的小鼠致死率测定方法(LD50),诸如小鼠膈神经膈肌测定方法的基于肌肉组织的测定方法(例如,如Bigalke,H.和Rummel A.,Toxins 7.12(2015):4895-4905)中所述的),基于细胞的测定方法(例如,如WO201349508或WO2012166943中所述的)或细胞外蛋白水解活性测定方法,例如Bo
Figure BDA0002607250570000111
(可从BioSentinel Inc.获得的肉毒杆菌神经毒素检测试剂盒)。
优选地,如果在给定的时间段和给定温度下存在不超过给定百分比的活性损失,则认为本发明的组合物是稳定的。
根据一个实施方案,如果在2至8℃下在3、6、12、18、24或36个月时细胞外蛋白水解活性损失不超过30%,则认为本发明的组合物是稳定的,例如在5℃下在6个月时细胞外蛋白水解活性损失不超过30%。优选地,如果在5℃下在3个月时,更优选在5℃下在6、12、18、24或36个月时,细胞外蛋白水解活性损失不超过20%,则认为本发明的组合物是稳定的。根据另一个实施方案,如果在室温下,例如在25℃下在3个月时细胞外蛋白水解活性损失不超过40%,则认为本发明的组合物是稳定的。优选地,如果在25℃下在3个月时,更优选地,在25℃下在6个月时细胞外蛋白水解活性损失不超过30%,则认为本发明的组合物是稳定的。根据另一个实施方案,如果在37℃下在2个月时细胞外蛋白水解活性损失不超过50%,则认为本发明的组合物是稳定的。细胞外蛋白水解活性可以用Bo
Figure BDA0002607250570000112
测定方法测量。
根据一个实施方案,如果在2至8℃下在2、3、6、12、18、24或36个月时MLD50单位损失不超过30%,则认为本发明的组合物是稳定的,例如在5℃下在6个月时MLD50单位损失不超过30%。优选地,如果在5℃下在2个月时,更优选在5℃下在3、6、12、18、24或36个月时MLD50单位损失不超过20%,则认为本发明的组合物是稳定的。根据另一个实施方案,如果在室温下,例如在25℃下,在2或3个月时MLD50单位损失不超过40%,则认为本发明的组合物是稳定的。优选地,如果在25℃下在3个月时,更优选在25℃下在6个月时,MLD50单位损失不超过30%,则认为本发明的组合物是稳定的。根据另一个实施方案,如果在37℃下在2个月时MLD50单位损失不超过50%,则认为本发明的组合物是稳定的。可以如上所述测量MLD50单位。
本发明的液体组合物可以储存在密封的小瓶或注射器中,例如玻璃小瓶或注射器,优选1型(或“体中性(body neutral)”)玻璃小瓶或注射器。优选地,小瓶或注射器中没有氧气或氧气很少。小瓶或注射器可以例如在氧气低于100ppm,优选低于50ppm的气氛中填充,并且氮气可以用作小瓶中的保护气氛。当使用玻璃小瓶时,它们可以例如用氯丁基橡胶或溴丁基橡胶塞盖住,其可以是Fluro
Figure BDA0002607250570000121
涂覆的塞子。优选地,将根据本发明的液体组合物储存在用Fluro
Figure BDA0002607250570000122
涂覆的塞子盖住的玻璃小瓶中。
根据一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο每毫升4至10000个LD50单位的肉毒杆菌神经毒素,
ο0.001至15%v/v聚山梨醇酯,
ο0.1至5mg/mL色氨酸,
ο10至500mM NaCl,
ο1至50mM KCI,
ο1至100mM磷酸钠,
pH值介于5.5和8之间,可在5℃下稳定6个月。
根据一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο每毫升10至2000个LD50单位的肉毒杆菌神经毒素,
ο0.005至2%v/v聚山梨醇酯,
ο0.1至5mg/mL色氨酸,
ο25至300mM NaCl,
ο1至10mM KCI,
ο2至50mM磷酸钠,
pH值介于6.0和7.5之间,可在5℃下稳定12个月。
根据一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο每毫升10至2000个LD50单位的肉毒杆菌神经毒素,
ο0.05至0.2%v/v聚山梨醇酯80,
ο0.1至5mg/mL色氨酸,
ο25至300mM NaCl,
ο1至10mM KCI,
ο2至50mM磷酸钠,
pH值介于6.0和7.5之间,可在5℃下稳定12个月。
根据一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒杆菌神经毒素A,
ο0.2%v/v聚山梨醇酯80,
ο1mg/mL色氨酸
ο140mM NaCl,
ο3mM KCI,
ο10mM磷酸钠,
其中所述组合物的pH约为6.6。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒杆菌神经毒素A,
ο0.04%v/v聚山梨醇酯80,
ο1mg/mL色氨酸
ο140mM NaCl,
ο3mM KCI,
ο10mM磷酸钠,
其中所述组合物的pH约为6.9。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒神经毒素B,
ο0.25%v/v聚山梨醇酯20,
ο4mg/mL色氨酸
ο140mM NaCl,
ο3mM KCI,
ο10mM磷酸钠,
其中所述组合物的pH约为7.4。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒杆菌神经毒素A,
ο0.01%v/v聚山梨醇酯80,
ο0.25mg/mL色氨酸
ο255mM NaCl,
ο2mM磷酸钠,
其中所述组合物的pH约为7.2。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒杆菌神经毒素A,
ο0.01%v/v聚山梨醇酯80,
ο0.25mg/mL色氨酸
ο255mM NaCl,
ο10mM KCI,
ο50mM磷酸钠,
其中所述组合物的pH约为6.3。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒杆菌神经毒素A,
ο1%v/v聚山梨醇酯80,
ο0.25mg/mL色氨酸
ο255mM NaCl,
ο50mM磷酸钠,
其中所述组合物的pH约为6.3。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒杆菌神经毒素A,
ο1%v/v聚山梨醇酯80,
ο3mg/mL色氨酸
ο255mM NaCl,
ο10mM KCI,
ο50mM磷酸钠,
其中所述组合物的pH约为7.2。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒杆菌神经毒素A,
ο0.1%v/v聚山梨醇酯80,
ο1.625mg/mL色氨酸
ο140mM NaCl,
ο3mM KCI,
ο10mM磷酸钠,
其中所述组合物的pH约为6.75。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒杆菌神经毒素A,
ο0.01%v/v聚山梨醇酯80,
ο1mg/mL色氨酸
ο140mM NaCl,
ο3mM KCI,
ο10mM磷酸钠,
其中所述组合物的pH约为6.75。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒杆菌神经毒素A,
ο0.1%v/v聚山梨醇酯80,
ο1mg/mL色氨酸
ο140mM NaCl,
ο3mM KCI,
ο10mM磷酸钠,
其中所述组合物的pH约为6.75。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒杆菌神经毒素A,
ο1%v/v聚山梨醇酯80,
ο1mg/mL色氨酸
ο140mM NaCl,
ο3mM KCI,
ο10mM磷酸钠,
其中所述组合物的pH约为6.75。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒神经毒素B,
ο15%v/v聚山梨醇酯20,
ο1mg/mL色氨酸
ο140mM NaCl,
ο3mM KCI,
ο10mM磷酸钠,
其中所述组合物的pH约为7.4。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒神经毒素B,
ο15%v/v聚山梨醇酯20,
ο4mg/mL色氨酸
ο140mM NaCl,
ο3mM KCI,
ο10mM磷酸钠,
其中所述组合物的pH约为7.4。
根据另一个实施方案,本发明的液体组合物包含以下或基本上由以下组成:
ο肉毒神经毒素B,
ο0.25%v/v聚山梨醇酯20,
ο4mg/mL色氨酸
ο140mM NaCl,
ο3mM KCI,
ο10mM磷酸钠,
其中所述组合物的pH约为7.4。
另一方面是本发明的液体组合物在治疗(therapy)中的用途。
本发明的液体组合物可用于治疗中以治疗或预防肌肉疾病、神经肌肉疾病、神经疾病、眼科疾病、疼痛疾病、心理疾病、关节疾病、炎性疾病、内分泌疾病或泌尿疾病。
例如,本发明的液体组合物可用于治疗或预防选自以下的疾病、病况或综合征:
·眼科学疾病,其选自眼睑痉挛、斜视(包括限制性或肌性斜视)、弱视、振动幻视(oscillopsia)、保护性上睑下垂、为保护角膜的治疗性上睑下垂、眼球震颤、内斜视(estropia)、复视、睑内翻、眼睑回缩、眼眶肌病、隐斜视、伴发性失调(concomitantmisalignment)、非伴发性失调、原发性或继发性内斜视或外斜视、核间性眼肌麻痹、反向偏斜、杜安氏综合征和上睑回缩;
·运动疾病,包括半面痉挛、斜颈、儿童或成人(如大脑性瘫痪、脑卒中后、多发性硬化、创伤性脑损伤或脊髓损伤患者)的痉挛状态、特发性局限性肌张力障碍、肌强直、书写痉挛、手肌张力障碍、VI型神经麻痹、口下颌肌张力障碍、头部震颤、迟发性运动障碍、迟发性肌张力障碍、职业性痉挛(包括音乐家的抽筋)、面神经麻痹、颌闭合痉挛、面部痉挛、联带运动(synkinesia)、震颤、原发性书写震颤、僵人综合症、足肌张力障碍、面瘫、臂痛及指动综合症(painful-arm-and-moving-fingers-syndrome)、抽动障碍、肌张力障碍性抽动(dystonic tics)、图雷特综合症、神经性肌强直、下颌震颤、外直肌麻痹、张力障碍性足内翻倒转(dystonic foot inversion)、颌肌张力障碍、兔唇综合征、小脑性震颤、III型神经麻痹、腭肌阵挛、静坐不能(akasthesia)、肌痉挛,IV型神经麻痹,步态呆板、躯干伸肌肌张力障碍、面神经麻痹后联带运动、继发性肌张力障碍、帕金森氏病、亨廷顿舞蹈病、癫痫,休克期(off period)肌张力障碍、头部破伤风、多发性纤维性肌阵挛和良性痉挛-肌束震颤综合征;
·耳鼻喉科学疾病,包括痉挛性发音困难、耳部疾病、听力损伤、耳内喀喇音(earclick)、耳鸣、眩晕、梅尼埃病、蜗神经功能障碍、口吃、环咽性吞咽困难、磨牙症、慢性抽吸中的喉闭合、声带肉芽肿、室性肌张力障碍、室性发音困难、突发性发声困难、牙关紧闭、打鼾、声音震颤、抽吸、舌突肌张力障碍、腭震颤、深度咬唇和喉肌张力障碍;第一次咬合综合症(First Bite Syndrome);
·胃肠疾病,包括失弛缓症、肛裂,便秘、颞下颌关节功能障碍、总胆管括约肌功能障碍、持续性总胆管括约肌高压、肠肌障碍、耻骨直肠肌综合征、肛门痉挛(anismus)、幽门痉挛、胆囊功能障碍、胃肠或食管动力障碍、弥漫性食管痉挛和胃轻瘫;
·泌尿生殖疾病,包括排尿肌括约肌失调、排尿肌反射亢进、神经性膀胱功能障碍(如帕金森病、脊髓损伤、中风或多发性硬化症患者中)、膀胱过度活动症、神经性排尿肌过度活动、膀胱痉挛、尿失禁、尿潴留、肥大性膀胱颈、排泄功能障碍、间质性膀胱炎、阴道痉挛、子宫内膜异位症、骨盆疼痛、前列腺增生(良性前列腺增生)、前列腺痛、前列腺癌和阴茎异常勃起;
·皮肤病学疾病,包括皮肤细胞增殖性疾病疾病、皮肤伤口、银屑病、酒渣鼻、痤疮;罕见的遗传性皮肤疾病,如干性粟粒疹综合征(Fox-Fordyce syndrome)或黑利-黑利二氏病(Hailey-Hailey disease);瘢痕疙瘩和增生性瘢痕减少;孔径减小;皮肤炎性病况;疼痛的皮肤炎性病况;
·疼痛疾病,包括背痛(上背痛,下背痛)、肌筋膜疼痛、紧张性头痛、纤维肌痛、疼痛综合征、肌痛、偏头痛、急性颈部扭伤、关节疼痛、术后疼痛、与肌肉痉挛无关的疼痛和与平滑肌疾病有关的疼痛;
·炎性疾病,包括胰腺炎、神经源性炎性疾病(包括痛风、肌腱炎、滑囊炎、皮肌炎和强直性脊柱炎);
·分泌性疾病,如腺体分泌过多、多汗症(包括腋窝多汗症、手掌多汗症和弗莱氏综合征)、多涎、流涎、臭汗症、粘液分泌过多、流泪过多、全分泌腺功能障碍;皮脂分泌过多;
·呼吸性疾病,包括鼻炎(包括过敏性鼻炎)、COPD、哮喘和肺结核;
·肥大性疾病,包括肌肉增大、咬肌肥大、肢端肥大症和伴有肌痛的神经源性胫骨前肌肥大;
·关节疾病,包括网球肘(或肘部上髁炎)、关节炎、髋关节炎、骨关节炎、肩关节旋转肌帽病变、类风湿性关节炎和腕管综合症;
·内分泌疾病,如2型糖尿病、高胰高血糖素血症(hyperglucagonism)、高胰岛素血症、低胰岛素血症、高钙血症、低钙血症、甲状腺疾病(包括格雷夫斯氏病、甲状腺炎、桥本甲状腺炎、甲状腺功能亢进症和甲状腺功能减退症)、甲状旁腺疾病(包括甲状旁腺功能亢进症和甲状旁腺功能减退症)、库欣综合征(Gushing's syndrome)和肥胖症;
·自身免疫性疾病,如系统性红斑狼疮;
·增殖性疾病,包括副神经节瘤、前列腺癌和骨肿瘤;
·创伤性损伤,包括运动损伤、肌肉损伤、肌腱创伤和骨折;和
·兽医用途(例如哺乳动物的固定、马绞痛、动物失弛缓症或动物肌肉痉挛)。
本发明的液体组合物还可以用于审美医学(aesthetic medicine)(用于改善美容外观),特别是用于治疗或预防皮肤皱纹,特别是面部皱纹,例如面部皱眉纹、眼部轮廓的皱纹、眉间皱眉纹、口角下垂、颈部皱纹(颈阔肌带)、下巴皱纹(颏肌纹、橘皮状皮肤、凹陷的下巴(dimpled chin)、额头纹、“抓伤的皮肤”皱纹、鼻托处理(nasal lift treatment)或睡纹。根据本发明的该方面,待治疗或预防以改善美容外观的受试者优选不患有上述任何疾病、病况或综合征。更优选地,所述受试者是健康受试者(即未患有任何疾病、病况或综合征)。
本发明的液体组合物可以与另一种治疗化合物组合使用。在一个实施方案中,本发明的液体组合物与用于治疗疼痛的镇痛化合物组合施用,特别是与如WO 2007/144493中所述的阿片样物质衍生物如吗啡组合施用,其内容通过引用并入本文。在另一个实施方案中,本发明的液体组合物与透明质酸组合施用,例如如WO2015/0444416中所述用于治疗前列腺癌,其内容通过引用并入本文。
本发明的另一方面是选自色氨酸和酪氨酸的氨基酸用于保护蛋白质性神经毒素免于在不含动物来源的蛋白质的液体组合物中降解的用途。
根据优选的实施方案,氨基酸是色氨酸,更优选L-色氨酸。
优选地,蛋白质性神经毒素是肉毒杆菌神经毒素。根据本发明的一个实施方案,肉毒杆菌神经毒素是复合物形式的肉毒杆菌神经毒素。根据另一个实施方案,肉毒杆菌神经毒素是高纯度肉毒杆菌神经毒素。根据本发明的一个实施方案,肉毒杆菌神经毒素是从其天然梭菌菌株纯化的肉毒杆菌神经毒素。根据另一个实施方案,肉毒杆菌神经毒素是在异源宿主例如大肠杆菌中重组产生的肉毒杆菌神经毒素。根据本发明,肉毒杆菌神经毒素可以是血清型A、B、C、D、E、F或G的BoNT。根据本发明,肉毒杆菌神经毒素可以是如上所述的修饰的肉毒杆菌神经毒素。根据本发明,重组肉毒杆菌神经毒素可以是如上所述的嵌合肉毒杆菌神经毒素。
根据优选的实施方案,氨基酸与表面活性剂和包含钠、氯和磷酸根离子的缓冲剂组合使用,并且液体组合物具有5.5至8的pH。优选地,表面活性剂是非离子表面活性剂,更优选聚山梨醇酯,例如PS20、PS60或PS80。最优选地,非离子表面活性剂是PS80。优选地,缓冲剂还包含钾离子。缓冲剂可以例如通过组合氯化钠、氯化钾和磷酸钠盐来获得。根据优选的实施方案,pH为6.0至7.5,例如6.3、6.35、6.4、6.45、6.5、6.55、6.6、6.65、6.7、6.75、6.8、6.85、6.9、6.95、7.0,、7.0、7.1、7.15、7.2、7.25、7.3、7.35、7.4、7.45或7.5。优选地,pH在距生理pH(其为约7.4)的一个单位内。
根据本发明用途的优选实施方案,液体组合物稳定2个月。例如,它在2至8℃下稳定2个月。根据一个实施方案,其在2至8℃下,例如在5℃下稳定3个月。根据优选的实施方案,它在2至8℃下,例如在5℃下稳定6个月。根据一个实施方案,其在2至8℃下,例如在5℃下稳定12个月。根据一个实施方案,其在2至8℃下,例如在5℃下稳定18个月。根据一个实施方案,其在2至8℃下,例如在5℃下稳定24个月。根据一个实施方案,其在2至8℃下,例如在5℃下稳定36个月。根据一个实施方案,其在室温下,例如在25℃下稳定3个月。根据一个实施方案,其在室温下,例如在25℃下稳定6个月。
实施例
1、制备稳定的液体肉毒杆菌毒素A制剂
制备含有15ng/mL高度纯化的BoNT/A,15%v/v聚山梨醇酯20,选自酪氨酸(Tyr)、色氨酸(Trp)和半胱氨酸(Cys)的氨基酸或甲硫氨酸(Met)、酪氨酸(Tyr)、色氨酸(Trp)和半胱氨酸(Cys)的混合物(Sigma Aldrich)和磷酸盐缓冲盐水(来自Calbiochem的PBS)(140mMNaCl,10mM磷酸钠和3mM KCl,pH 7.4,25℃)的液体肉毒杆菌毒素制剂,使用0.22μm PVDF(聚偏氟乙烯)过滤器过滤,并在40℃下在硅化的2mL玻璃注射器中储存6天,之后对每种制剂进行效力测试。
对于效力测试,将含有制剂的注射器排至2mL玻璃瓶(Chromacol,Gold)中,其盖子含有PTFE处理的橡胶隔垫(Chromacol),或至1.7mL塑料微量离心管(Axygen,MaximumRecovery)中,两者均具有低蛋白质吸附特性。随后使用含有3%人血清白蛋白(HSA)的0.9%NaCl溶液稀释制剂。对于每种制剂,在进行稀释的同一天将50μL样品注射到小鼠的腓肠肌中。监测小鼠3天并记录麻痹程度。
结果如表1所示。
表1-氨基酸添加对BoNT/A稳定性的加速储存试验(在40℃下6天)。小鼠中的麻痹 结果:-=未分析,WN=无记录,PA=麻痹,
Figure BDA0002607250570000223
Figure BDA0002607250570000222
发现酪氨酸和色氨酸对BoNT/A降解具有保护作用。发现色氨酸具有最强的保护作用。半胱氨酸以及含有所有4种氨基酸的混合物没有保护作用。
2、制备稳定的液体肉毒杆菌毒素B制剂
制备含有350ng/mL高度纯化的BoNT/B,15%v/v聚山梨醇酯20,选自酪氨酸(Tyr)、色氨酸(Trp)和半胱氨酸(Cys)的氨基酸或甲硫氨酸(Met)、酪氨酸(Tyr)、色氨酸(Trp)和半胱氨酸(Cys)的混合物,以及pH7.4的磷酸盐缓冲盐水(PBS)的液体肉毒杆菌毒素制剂,使用0.22μm过滤器过滤,并在40℃下在硅化的2mL玻璃注射器中储存两周,然后,如上所述对每种制剂进行效力试验。
结果如表2所示。
表2-氨基酸添加对BoNT/B稳定性的加速储存试验(在40℃下两周)。小鼠中的麻痹 结果:-=未分析,WN=无记录,PA=麻痹,
Figure BDA0002607250570000232
Figure BDA0002607250570000231
发现酪氨酸和色氨酸对BoNT/B降解具有保护作用。半胱氨酸以及含有所有4种氨基酸的混合物也具有保护作用,但程度较弱。
3、评估不同浓度的色氨酸和聚山梨醇酯20
制备含有高度纯化的BoNT/A或BoNT/B和各种浓度的聚山梨醇酯20(PS20)和色氨酸和pH7.4的磷酸盐缓冲盐水(PBS)的液体肉毒杆菌毒素制剂,使用0.22μm过滤器过滤并储存在硅化的2mL玻璃注射器中。如上所述对每种制剂进行后肢麻痹效力测试。
结果如表3所示。
表3-Trp和聚山梨醇酯20(PS20)浓度对BoNT/A或BoNT/B稳定性的评估。小鼠中的 麻痹结果:-=未分析,WN=无记录,PA=麻痹,
Figure BDA0002607250570000242
Figure BDA0002607250570000241
麻痹程度(PA):1、脚趾受影响;2、后肢轻微麻木;3、两只后肢都麻痹;4、后肢麻痹;来自纯化的洗脱缓冲液(5):50mM乙酸钠pH 4.5,含0.2%(v:v)聚山梨醇酯20和400mM氯化钠。*可能发生了25℃8mg/mL Trp 0.25%聚山梨醇酯20的两种BoNT/A稀释液的混合。
4、评估BoNT/B制剂中不同的盐浓度
制备含有100ng/mL高度纯化的BoNT/B,聚山梨醇酯20,来自各种氨基酸供应商的色氨酸和选自PBS pH 7.4(Calbiochem)、12nM磷酸盐缓冲液pH 7(Apoteket)和20mM乙酸钠缓冲液(NaAc)pH5.5(来自Fluka的NaAc和来自Merck的乙酸)的缓冲液的液体肉毒杆菌毒素制剂,使用0.22μm过滤器过滤并储存在硅化的2mL玻璃注射器中。如上所述对每种制剂进行后肢麻痹效力测试。
结果如表4所示。
表4-不同盐浓度对BoNT/B稳定性的评估。小鼠中的麻痹结果:-=未分析,WN=无 记录,PA=麻痹,
Figure BDA0002607250570000252
Figure BDA0002607250570000251
Figure BDA0002607250570000261
1、丧失一些功能;2、弱麻痹
结果显示含有PBS缓冲液(含有钠、氯、磷酸根和钾离子)的制剂在肉毒杆菌毒素的稳定性方面起作用。
5、评估不同的稳定剂
制备含有15ng/mL高度纯化的BoNT/A,聚山梨醇酯20(PS20)或聚山梨醇酯80(PS80)或HSA,色氨酸和PBS的液体肉毒杆菌毒素制剂,使用0.22μm过滤器过滤并储存在硅化的2mL玻璃注射器中。如上所述对每种制剂进行后肢麻痹效力测试。
结果如表5所示。
表5-不同表面活性剂对BoNT/A稳定性的评价。小鼠中的麻痹结果:-=未分析,WN =无记录,PA=麻痹,
Figure BDA0002607250570000263
Figure BDA0002607250570000262
Figure BDA0002607250570000271
1、双后肢严重麻痹;2、角爪(angles paws);3、严重麻痹
6、评估不同的制剂
如上所述制备含有10ng/mL高度纯化的BoNT/A,0.25%PS80,1mg/mL色氨酸和PBS的液体肉毒杆菌毒素制剂。通过添加HCl将pH调节至6.6和7.0。每种制剂在40℃下储存5周。
然后将每种制剂稀释10倍,并如上所述进行后肢麻痹效力测试(每次注射0.05ng)。在两种情况下,在第3天均观察到后肢麻痹。pH 6.6制剂的麻痹更强烈。
7、评估不同的制剂
如上所述制备含有0.3ng/mL高度纯化的BoNT/A,选自PS20和PS80的聚山梨醇酯,1mg/mL色氨酸和pH7.4的12mM PBS的液体肉毒杆菌毒素制剂。通过加入1.2M HCl将每种制剂的pH调节至pH 6.6或6.9。
在一种浓度,0.2%w/v,测试聚山梨醇酯20,该浓度相当于其CMC(临界胶束浓度,在21℃下约0.01%w/v)的约20倍。测试的聚山梨醇酯80为0.04%和0.2%w/v,分别对应于其CMC(在21℃下约0.002%w/v)的约20和100倍。
表6-聚山梨醇酯和pH的选择
Figure BDA0002607250570000272
Figure BDA0002607250570000281
对于每种制剂,将0.5mL体积装入1mL长玻璃注射器(BD)中并用涂有碳氟化合物的柱塞密封。
如上所述,通过对小鼠的后肢麻痹试验测量效力。
在5℃和25℃下储存6个月后,在任何制剂中均未观察到效力降低。
8、评估不同的制剂
用不同浓度的聚山梨醇酯80、色氨酸、磷酸钠、氯化钠、氯化钾和不同的pH制备含有高度纯化的A型肉毒杆菌神经毒素的19种不同制剂。每种制剂的目标标称效力为500U/mL。将每种制剂脱气,通过0.2μm过滤器过滤并装入小瓶中。氮气用作小瓶中的保护气氛。填充在厌氧室中进行。将每种制剂以1mL等分试样在氮气气氛下装入2mL玻璃瓶中,该玻璃瓶盖有用铝制易拉密封盖密封的Fluro
Figure BDA0002607250570000283
塞子并直立储存。
使用Bo
Figure BDA0002607250570000284
在5℃、25℃和37℃下评估19种制剂的稳定性以测量效力。
表7-赋形剂组合物
Figure BDA0002607250570000282
Figure BDA0002607250570000291
表8-包装组件
物件 物件编号,供应商
I类plus透明硼硅玻璃瓶,2mL 1097221,Schott
灰色涂覆Flurotec的溴化丁基塞Westar RS,13mm 1356 4023/50,West
铝制易拉密封盖,13mm 5920-6623,West
对于所有配方,溶液保持透明且大多数部分无色。
在该研究中测试的赋形剂浓度在测试的时间间隔内不影响制剂的pH。效力结果列于表9中。
表9-Botest效力结果
Figure BDA0002607250570000292
Figure BDA0002607250570000301
对于几种组合物,在5℃下在6个月时效力损失不超过30%和/或在25℃下在3个月时效力损失不超过约40%和/或在37℃下在2个月时效力损失不超过约50%。
9、评估PS 60
用0.1%(v/v)PS60、1mg/mL L-色氨酸、10mM磷酸钠、140mM氯化钠、3mM氯化钾和注射用水制备含有高度纯化的A型肉毒杆菌神经毒素的制剂。用HCl将pH调节至6.75。该制剂的目标标称效力为100U/mL。将制剂脱气,通过0.2μm过滤器过滤,并在厌氧室中在氮气氛下无菌填充到2mL小瓶中,填充体积为1mL。氮气用作小瓶中的保护气氛。用密封有铝制易拉密封盖的Fluro
Figure BDA0002607250570000303
塞子盖住小瓶。
表10-包装组件
Figure BDA0002607250570000302
Figure BDA0002607250570000311
通过如本文所述的MLD50测试测量了在37℃和25℃下随时间的效力。
在37℃下,9周后的剩余效力为初始效力的约50-55%。
在25℃下,3个月后的剩余效力是初始效力的约80%。
序列表
<110> 益普生生物制药有限公司(IPSEN BIOPHARM Ltd)
<120> 用色氨酸或酪氨酸稳定的液体神经毒素制剂
<130> IBGA 001-WO(2)
<150> PCT/EP2016/062085
<151> 2016-05-27
<160> 7
<170> PatentIn version 3.5
<210> 1
<211> 1296
<212> PRT
<213> 肉毒杆菌(Clostridium botulinum)
<400> 1
Met Pro Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly
1 5 10 15
Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro
20 25 30
Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg
35 40 45
Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu
50 55 60
Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr
65 70 75 80
Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu
85 90 95
Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val
100 105 110
Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys
115 120 125
Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr
130 135 140
Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile
145 150 155 160
Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr
165 170 175
Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe
180 185 190
Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu
195 200 205
Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu
210 215 220
Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn
225 230 235 240
Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu
245 250 255
Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys
260 265 270
Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn
275 280 285
Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val
290 295 300
Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys
305 310 315 320
Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu
325 330 335
Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp
340 345 350
Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn
355 360 365
Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr
370 375 380
Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn
385 390 395 400
Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu
405 410 415
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg
420 425 430
Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys
435 440 445
Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe
450 455 460
Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu
465 470 475 480
Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu
485 490 495
Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro
500 505 510
Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu
515 520 525
Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu
530 535 540
Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu
545 550 555 560
His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu
565 570 575
Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys
580 585 590
Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu
595 600 605
Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr
610 615 620
Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu
645 650 655
Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala
660 665 670
Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys
675 680 685
Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu
690 695 700
Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys
705 710 715 720
Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu
725 730 735
Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn
740 745 750
Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp
755 760 765
Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile
770 775 780
Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met
785 790 795 800
Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys
805 810 815
Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly
820 825 830
Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp
835 840 845
Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser
850 855 860
Thr Phe Thr Glu Tyr Ile Lys Asn Ile Ile Asn Thr Ser Ile Leu Asn
865 870 875 880
Leu Arg Tyr Glu Ser Asn His Leu Ile Asp Leu Ser Arg Tyr Ala Ser
885 890 895
Lys Ile Asn Ile Gly Ser Lys Val Asn Phe Asp Pro Ile Asp Lys Asn
900 905 910
Gln Ile Gln Leu Phe Asn Leu Glu Ser Ser Lys Ile Glu Val Ile Leu
915 920 925
Lys Asn Ala Ile Val Tyr Asn Ser Met Tyr Glu Asn Phe Ser Thr Ser
930 935 940
Phe Trp Ile Arg Ile Pro Lys Tyr Phe Asn Ser Ile Ser Leu Asn Asn
945 950 955 960
Glu Tyr Thr Ile Ile Asn Cys Met Glu Asn Asn Ser Gly Trp Lys Val
965 970 975
Ser Leu Asn Tyr Gly Glu Ile Ile Trp Thr Leu Gln Asp Thr Gln Glu
980 985 990
Ile Lys Gln Arg Val Val Phe Lys Tyr Ser Gln Met Ile Asn Ile Ser
995 1000 1005
Asp Tyr Ile Asn Arg Trp Ile Phe Val Thr Ile Thr Asn Asn Arg
1010 1015 1020
Leu Asn Asn Ser Lys Ile Tyr Ile Asn Gly Arg Leu Ile Asp Gln
1025 1030 1035
Lys Pro Ile Ser Asn Leu Gly Asn Ile His Ala Ser Asn Asn Ile
1040 1045 1050
Met Phe Lys Leu Asp Gly Cys Arg Asp Thr His Arg Tyr Ile Trp
1055 1060 1065
Ile Lys Tyr Phe Asn Leu Phe Asp Lys Glu Leu Asn Glu Lys Glu
1070 1075 1080
Ile Lys Asp Leu Tyr Asp Asn Gln Ser Asn Ser Gly Ile Leu Lys
1085 1090 1095
Asp Phe Trp Gly Asp Tyr Leu Gln Tyr Asp Lys Pro Tyr Tyr Met
1100 1105 1110
Leu Asn Leu Tyr Asp Pro Asn Lys Tyr Val Asp Val Asn Asn Val
1115 1120 1125
Gly Ile Arg Gly Tyr Met Tyr Leu Lys Gly Pro Arg Gly Ser Val
1130 1135 1140
Met Thr Thr Asn Ile Tyr Leu Asn Ser Ser Leu Tyr Arg Gly Thr
1145 1150 1155
Lys Phe Ile Ile Lys Lys Tyr Ala Ser Gly Asn Lys Asp Asn Ile
1160 1165 1170
Val Arg Asn Asn Asp Arg Val Tyr Ile Asn Val Val Val Lys Asn
1175 1180 1185
Lys Glu Tyr Arg Leu Ala Thr Asn Ala Ser Gln Ala Gly Val Glu
1190 1195 1200
Lys Ile Leu Ser Ala Leu Glu Ile Pro Asp Val Gly Asn Leu Ser
1205 1210 1215
Gln Val Val Val Met Lys Ser Lys Asn Asp Gln Gly Ile Thr Asn
1220 1225 1230
Lys Cys Lys Met Asn Leu Gln Asp Asn Asn Gly Asn Asp Ile Gly
1235 1240 1245
Phe Ile Gly Phe His Gln Phe Asn Asn Ile Ala Lys Leu Val Ala
1250 1255 1260
Ser Asn Trp Tyr Asn Arg Gln Ile Glu Arg Ser Ser Arg Thr Leu
1265 1270 1275
Gly Cys Ser Trp Glu Phe Ile Pro Val Asp Asp Gly Trp Gly Glu
1280 1285 1290
Arg Pro Leu
1295
<210> 2
<211> 1291
<212> PRT
<213> 肉毒杆菌(Clostridium botulinum)
<400> 2
Met Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn
1 5 10 15
Asn Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg
20 25 30
Tyr Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu
35 40 45
Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly
50 55 60
Ile Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn
65 70 75 80
Thr Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe
85 90 95
Asn Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met Ile
100 105 110
Ile Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu
115 120 125
Phe Asn Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn
130 135 140
Pro Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile
145 150 155 160
Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly
165 170 175
Ile Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln
180 185 190
Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu
195 200 205
Asn Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro
210 215 220
Ala Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr
225 230 235 240
Gly Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe
245 250 255
Phe Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile
275 280 285
Tyr Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn
290 295 300
Lys Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr
305 310 315 320
Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly
325 330 335
Lys Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu
340 345 350
Met Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys
355 360 365
Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys
370 375 380
Asn Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile
385 390 395 400
Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile
405 410 415
Asn Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr
420 425 430
Lys Ile Gln Met Cys Lys Ser Val Lys Ala Pro Gly Ile Cys Ile Asp
435 440 445
Val Asp Asn Glu Asp Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser
450 455 460
Asp Asp Leu Ser Lys Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn
465 470 475 480
Tyr Ile Glu Asn Asp Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp
485 490 495
Leu Ile Ser Lys Ile Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr
500 505 510
Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys
515 520 525
Lys Ile Phe Thr Asp Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln
530 535 540
Thr Phe Pro Leu Asp Ile Arg Asp Ile Ser Leu Thr Ser Ser Phe Asp
545 550 555 560
Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp
565 570 575
Tyr Ile Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly
580 585 590
Trp Val Lys Gln Ile Val Asn Asp Phe Val Ile Glu Ala Asn Lys Ser
595 600 605
Asn Thr Met Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Ile
610 615 620
Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu
625 630 635 640
Asn Ala Phe Glu Ile Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro
645 650 655
Glu Leu Leu Ile Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile
660 665 670
Asp Asn Lys Asn Lys Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys
675 680 685
Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp
690 695 700
Leu Ser Thr Val Asn Thr Gln Phe Tyr Thr Ile Lys Glu Gly Met Tyr
705 710 715 720
Lys Ala Leu Asn Tyr Gln Ala Gln Ala Leu Glu Glu Ile Ile Lys Tyr
725 730 735
Arg Tyr Asn Ile Tyr Ser Glu Lys Glu Lys Ser Asn Ile Asn Ile Asp
740 745 750
Phe Asn Asp Ile Asn Ser Lys Leu Asn Glu Gly Ile Asn Gln Ala Ile
755 760 765
Asp Asn Ile Asn Asn Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met
770 775 780
Lys Lys Met Ile Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn
785 790 795 800
Thr Leu Lys Lys Asn Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr
805 810 815
Leu Ile Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu
820 825 830
Lys Thr Ile Met Pro Phe Asp Leu Ser Ile Tyr Thr Asn Asp Thr Ile
835 840 845
Leu Ile Glu Met Phe Asn Lys Tyr Asn Ser Glu Ile Leu Asn Asn Ile
850 855 860
Ile Leu Asn Leu Arg Tyr Lys Asp Asn Asn Leu Ile Asp Leu Ser Gly
865 870 875 880
Tyr Gly Ala Lys Val Glu Val Tyr Asp Gly Val Glu Leu Asn Asp Lys
885 890 895
Asn Gln Phe Lys Leu Thr Ser Ser Ala Asn Ser Lys Ile Arg Val Thr
900 905 910
Gln Asn Gln Asn Ile Ile Phe Asn Ser Val Phe Leu Asp Phe Ser Val
915 920 925
Ser Phe Trp Ile Arg Ile Pro Lys Tyr Lys Asn Asp Gly Ile Gln Asn
930 935 940
Tyr Ile His Asn Glu Tyr Thr Ile Ile Asn Cys Met Lys Asn Asn Ser
945 950 955 960
Gly Trp Lys Ile Ser Ile Arg Gly Asn Arg Ile Ile Trp Thr Leu Ile
965 970 975
Asp Ile Asn Gly Lys Thr Lys Ser Val Phe Phe Glu Tyr Asn Ile Arg
980 985 990
Glu Asp Ile Ser Glu Tyr Ile Asn Arg Trp Phe Phe Val Thr Ile Thr
995 1000 1005
Asn Asn Leu Asn Asn Ala Lys Ile Tyr Ile Asn Gly Lys Leu Glu
1010 1015 1020
Ser Asn Thr Asp Ile Lys Asp Ile Arg Glu Val Ile Ala Asn Gly
1025 1030 1035
Glu Ile Ile Phe Lys Leu Asp Gly Asp Ile Asp Arg Thr Gln Phe
1040 1045 1050
Ile Trp Met Lys Tyr Phe Ser Ile Phe Asn Thr Glu Leu Ser Gln
1055 1060 1065
Ser Asn Ile Glu Glu Arg Tyr Lys Ile Gln Ser Tyr Ser Glu Tyr
1070 1075 1080
Leu Lys Asp Phe Trp Gly Asn Pro Leu Met Tyr Asn Lys Glu Tyr
1085 1090 1095
Tyr Met Phe Asn Ala Gly Asn Lys Asn Ser Tyr Ile Lys Leu Lys
1100 1105 1110
Lys Asp Ser Pro Val Gly Glu Ile Leu Thr Arg Ser Lys Tyr Asn
1115 1120 1125
Gln Asn Ser Lys Tyr Ile Asn Tyr Arg Asp Leu Tyr Ile Gly Glu
1130 1135 1140
Lys Phe Ile Ile Arg Arg Lys Ser Asn Ser Gln Ser Ile Asn Asp
1145 1150 1155
Asp Ile Val Arg Lys Glu Asp Tyr Ile Tyr Leu Asp Phe Phe Asn
1160 1165 1170
Leu Asn Gln Glu Trp Arg Val Tyr Thr Tyr Lys Tyr Phe Lys Lys
1175 1180 1185
Glu Glu Glu Lys Leu Phe Leu Ala Pro Ile Ser Asp Ser Asp Glu
1190 1195 1200
Phe Tyr Asn Thr Ile Gln Ile Lys Glu Tyr Asp Glu Gln Pro Thr
1205 1210 1215
Tyr Ser Cys Gln Leu Leu Phe Lys Lys Asp Glu Glu Ser Thr Asp
1220 1225 1230
Glu Ile Gly Leu Ile Gly Ile His Arg Phe Tyr Glu Ser Gly Ile
1235 1240 1245
Val Phe Glu Glu Tyr Lys Asp Tyr Phe Cys Ile Ser Lys Trp Tyr
1250 1255 1260
Leu Lys Glu Val Lys Arg Lys Pro Tyr Asn Leu Lys Leu Gly Cys
1265 1270 1275
Asn Trp Gln Phe Ile Pro Lys Asp Glu Gly Trp Thr Glu
1280 1285 1290
<210> 3
<211> 1291
<212> PRT
<213> 肉毒杆菌(Clostridium botulinum)
<400> 3
Met Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp Pro Val Asp Asn
1 5 10 15
Lys Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr Leu Ala Asn Glu
20 25 30
Pro Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp Val Ile Pro Asp
35 40 45
Arg Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys Pro Pro Arg Val
50 55 60
Thr Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr Leu Ser Thr Asp
65 70 75 80
Ser Asp Lys Asp Pro Phe Leu Lys Glu Ile Ile Lys Leu Phe Lys Arg
85 90 95
Ile Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr Arg Leu Ser Thr
100 105 110
Asp Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile Asn Thr Phe Asp
115 120 125
Phe Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr Arg Gln Gly Asn
130 135 140
Asn Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val Ile Ile Thr Gly
145 150 155 160
Pro Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr Phe Lys Leu Thr
165 170 175
Asn Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala Leu Ser Ile Ile
180 185 190
Ser Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn Ala Thr Asn Asp
195 200 205
Val Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys Met Asp Pro Ile
210 215 220
Leu Ile Leu Met His Glu Leu Asn His Ala Met His Asn Leu Tyr Gly
225 230 235 240
Ile Ala Ile Pro Asn Asp Gln Thr Ile Ser Ser Val Thr Ser Asn Ile
245 250 255
Phe Tyr Ser Gln Tyr Asn Val Lys Leu Glu Tyr Ala Glu Ile Tyr Ala
260 265 270
Phe Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser Ala Arg Lys Tyr
275 280 285
Phe Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile Ala Lys Arg Leu
290 295 300
Asn Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn Lys Tyr Ile Gly
305 310 315 320
Glu Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe Val Val Glu Ser
325 330 335
Ser Gly Glu Val Thr Val Asn Arg Asn Lys Phe Val Glu Leu Tyr Asn
340 345 350
Glu Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala Lys Ile Tyr Asn
355 360 365
Val Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr Thr Pro Val Thr
370 375 380
Ala Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln Asn Gly Phe Asn
385 390 395 400
Ile Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu Ser
405 410 415
Arg Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn Met Leu Tyr Leu
420 425 430
Phe Thr Lys Phe Cys His Lys Ala Ile Asp Gly Arg Ser Leu Tyr Asn
435 440 445
Lys Thr Leu Asp Cys Arg Glu Leu Leu Val Lys Asn Thr Asp Leu Pro
450 455 460
Phe Ile Gly Asp Ile Ser Asp Val Lys Thr Asp Ile Phe Leu Arg Lys
465 470 475 480
Asp Ile Asn Glu Glu Thr Glu Val Ile Tyr Tyr Pro Asp Asn Val Ser
485 490 495
Val Asp Gln Val Ile Leu Ser Lys Asn Thr Ser Glu His Gly Gln Leu
500 505 510
Asp Leu Leu Tyr Pro Ser Ile Asp Ser Glu Ser Glu Ile Leu Pro Gly
515 520 525
Glu Asn Gln Val Phe Tyr Asp Asn Arg Thr Gln Asn Val Asp Tyr Leu
530 535 540
Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asp Asn Val Glu
545 550 555 560
Asp Phe Thr Phe Thr Arg Ser Ile Glu Glu Ala Leu Asp Asn Ser Ala
565 570 575
Lys Val Tyr Thr Tyr Phe Pro Thr Leu Ala Asn Lys Val Asn Ala Gly
580 585 590
Val Gln Gly Gly Leu Phe Leu Met Trp Ala Asn Asp Val Val Glu Asp
595 600 605
Phe Thr Thr Asn Ile Leu Arg Lys Asp Thr Leu Asp Lys Ile Ser Asp
610 615 620
Val Ser Ala Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Ser Asn
625 630 635 640
Ser Val Arg Arg Gly Asn Phe Thr Glu Ala Phe Ala Val Thr Gly Val
645 650 655
Thr Ile Leu Leu Glu Ala Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly
660 665 670
Ala Phe Val Ile Tyr Ser Lys Val Gln Glu Arg Asn Glu Ile Ile Lys
675 680 685
Thr Ile Asp Asn Cys Leu Glu Gln Arg Ile Lys Arg Trp Lys Asp Ser
690 695 700
Tyr Glu Trp Met Met Gly Thr Trp Leu Ser Arg Ile Ile Thr Gln Phe
705 710 715 720
Asn Asn Ile Ser Tyr Gln Met Tyr Asp Ser Leu Asn Tyr Gln Ala Gly
725 730 735
Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser
740 745 750
Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu
755 760 765
Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg
770 775 780
Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile
785 790 795 800
Asp Glu Leu Asn Glu Phe Asp Arg Asn Thr Lys Ala Lys Leu Ile Asn
805 810 815
Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Lys Leu
820 825 830
Lys Ala Lys Val Asn Asn Ser Phe Gln Asn Thr Ile Pro Phe Asn Ile
835 840 845
Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr
850 855 860
Phe Asn Asn Ile Asn Asp Ser Lys Ile Leu Ser Leu Gln Asn Arg Lys
865 870 875 880
Asn Thr Leu Val Asp Thr Ser Gly Tyr Asn Ala Glu Val Ser Glu Glu
885 890 895
Gly Asp Val Gln Leu Asn Pro Ile Phe Pro Phe Asp Phe Lys Leu Gly
900 905 910
Ser Ser Gly Glu Asp Arg Gly Lys Val Ile Val Thr Gln Asn Glu Asn
915 920 925
Ile Val Tyr Asn Ser Met Tyr Glu Ser Phe Ser Ile Ser Phe Trp Ile
930 935 940
Arg Ile Asn Lys Trp Val Ser Asn Leu Pro Gly Tyr Thr Ile Ile Asp
945 950 955 960
Ser Val Lys Asn Asn Ser Gly Trp Ser Ile Gly Ile Ile Ser Asn Phe
965 970 975
Leu Val Phe Thr Leu Lys Gln Asn Glu Asp Ser Glu Gln Ser Ile Asn
980 985 990
Phe Ser Tyr Asp Ile Ser Asn Asn Ala Pro Gly Tyr Asn Lys Trp Phe
995 1000 1005
Phe Val Thr Val Thr Asn Asn Met Met Gly Asn Met Lys Ile Tyr
1010 1015 1020
Ile Asn Gly Lys Leu Ile Asp Thr Ile Lys Val Lys Glu Leu Thr
1025 1030 1035
Gly Ile Asn Phe Ser Lys Thr Ile Thr Phe Glu Ile Asn Lys Ile
1040 1045 1050
Pro Asp Thr Gly Leu Ile Thr Ser Asp Ser Asp Asn Ile Asn Met
1055 1060 1065
Trp Ile Arg Asp Phe Tyr Ile Phe Ala Lys Glu Leu Asp Gly Lys
1070 1075 1080
Asp Ile Asn Ile Leu Phe Asn Ser Leu Gln Tyr Thr Asn Val Val
1085 1090 1095
Lys Asp Tyr Trp Gly Asn Asp Leu Arg Tyr Asn Lys Glu Tyr Tyr
1100 1105 1110
Met Val Asn Ile Asp Tyr Leu Asn Arg Tyr Met Tyr Ala Asn Ser
1115 1120 1125
Arg Gln Ile Val Phe Asn Thr Arg Arg Asn Asn Asn Asp Phe Asn
1130 1135 1140
Glu Gly Tyr Lys Ile Ile Ile Lys Arg Ile Arg Gly Asn Thr Asn
1145 1150 1155
Asp Thr Arg Val Arg Gly Gly Asp Ile Leu Tyr Phe Asp Met Thr
1160 1165 1170
Ile Asn Asn Lys Ala Tyr Asn Leu Phe Met Lys Asn Glu Thr Met
1175 1180 1185
Tyr Ala Asp Asn His Ser Thr Glu Asp Ile Tyr Ala Ile Gly Leu
1190 1195 1200
Arg Glu Gln Thr Lys Asp Ile Asn Asp Asn Ile Ile Phe Gln Ile
1205 1210 1215
Gln Pro Met Asn Asn Thr Tyr Tyr Tyr Ala Ser Gln Ile Phe Lys
1220 1225 1230
Ser Asn Phe Asn Gly Glu Asn Ile Ser Gly Ile Cys Ser Ile Gly
1235 1240 1245
Thr Tyr Arg Phe Arg Leu Gly Gly Asp Trp Tyr Arg His Asn Tyr
1250 1255 1260
Leu Val Pro Thr Val Lys Gln Gly Asn Tyr Ala Ser Leu Leu Glu
1265 1270 1275
Ser Thr Ser Thr His Trp Gly Phe Val Pro Val Ser Glu
1280 1285 1290
<210> 4
<211> 1276
<212> PRT
<213> 肉毒杆菌(Clostridium botulinum)
<400> 4
Met Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp
1 5 10 15
Asn Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr
20 25 30
Pro Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu
35 40 45
Arg Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro
50 55 60
Thr Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp
65 70 75 80
Glu Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg
85 90 95
Ile Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val
100 105 110
Gly Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp
115 120 125
Phe Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly
130 135 140
Ser Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly
145 150 155 160
Pro Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly
165 170 175
Gln Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu
180 185 190
Lys Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn
195 200 205
Gln Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val
210 215 220
Ile Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly
225 230 235 240
Ile Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly
245 250 255
Phe Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr
260 265 270
Phe Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln
275 280 285
Leu Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu
290 295 300
Asn Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp
305 310 315 320
Lys Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn
325 330 335
Thr Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser
340 345 350
Asp Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn
355 360 365
Val Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe
370 375 380
Ala Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn
385 390 395 400
Leu Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu
405 410 415
Arg Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu
420 425 430
Phe Thr Lys Val Cys Leu Arg Leu Thr Lys Asn Ser Arg Asp Asp Ser
435 440 445
Thr Cys Ile Lys Val Lys Asn Asn Arg Leu Pro Tyr Val Ala Asp Lys
450 455 460
Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys Ile Ile Thr Asp Glu
465 470 475 480
Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser Leu Asp Glu Ser Ile
485 490 495
Leu Asp Gly Gln Val Pro Ile Asn Pro Glu Ile Val Asp Pro Leu Leu
500 505 510
Pro Asn Val Asn Met Glu Pro Leu Asn Leu Pro Gly Glu Glu Ile Val
515 520 525
Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr
530 535 540
Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn Val Glu Asn Ile Thr Leu
545 550 555 560
Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys Ile Tyr Thr
565 570 575
Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val Gln Ala Gly
580 585 590
Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu Asp Phe Thr Thr Asn
595 600 605
Ile Met Lys Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser Val Ile
610 615 620
Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Ser Ala Leu Arg
625 630 635 640
Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly Val Ala Phe Leu Leu
645 650 655
Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val Phe Thr Phe
660 665 670
Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr Ile Glu Asn
675 680 685
Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr Gln Trp Met
690 695 700
Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln Phe Asn His Ile Asn
705 710 715 720
Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala Asp Ala Ile Lys Ala
725 730 735
Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys Glu Asn
740 745 750
Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val Lys Ile
755 760 765
Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys Ser Val
770 775 780
Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu Leu Asn
785 790 795 800
Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile Asn Leu Ile Asp Ser
805 810 815
His Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys Ala Lys Val
820 825 830
Asn Glu Ser Phe Glu Asn Thr Met Pro Phe Asn Ile Phe Ser Tyr Thr
835 840 845
Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe Asn Ser Ile
850 855 860
Asn Asp Ser Lys Ile Leu Ser Leu Gln Asn Lys Lys Asn Ala Leu Val
865 870 875 880
Asp Thr Ser Gly Tyr Asn Ala Glu Val Arg Val Gly Asp Asn Val Gln
885 890 895
Leu Asn Thr Ile Tyr Thr Asn Asp Phe Lys Leu Ser Ser Ser Gly Asp
900 905 910
Lys Ile Ile Val Asn Leu Asn Asn Asn Ile Leu Tyr Ser Ala Ile Tyr
915 920 925
Glu Asn Ser Ser Val Ser Phe Trp Ile Lys Ile Ser Lys Asp Leu Thr
930 935 940
Asn Ser His Asn Glu Tyr Thr Ile Ile Asn Ser Ile Glu Gln Asn Ser
945 950 955 960
Gly Trp Lys Leu Cys Ile Arg Asn Gly Asn Ile Glu Trp Ile Leu Gln
965 970 975
Asp Val Asn Arg Lys Tyr Lys Ser Leu Ile Phe Asp Tyr Ser Glu Ser
980 985 990
Leu Ser His Thr Gly Tyr Thr Asn Lys Trp Phe Phe Val Thr Ile Thr
995 1000 1005
Asn Asn Ile Met Gly Tyr Met Lys Leu Tyr Ile Asn Gly Glu Leu
1010 1015 1020
Lys Gln Ser Gln Lys Ile Glu Asp Leu Asp Glu Val Lys Leu Asp
1025 1030 1035
Lys Thr Ile Val Phe Gly Ile Asp Glu Asn Ile Asp Glu Asn Gln
1040 1045 1050
Met Leu Trp Ile Arg Asp Phe Asn Ile Phe Ser Lys Glu Leu Ser
1055 1060 1065
Asn Glu Asp Ile Asn Ile Val Tyr Glu Gly Gln Ile Leu Arg Asn
1070 1075 1080
Val Ile Lys Asp Tyr Trp Gly Asn Pro Leu Lys Phe Asp Thr Glu
1085 1090 1095
Tyr Tyr Ile Ile Asn Asp Asn Tyr Ile Asp Arg Tyr Ile Ala Pro
1100 1105 1110
Glu Ser Asn Val Leu Val Leu Val Gln Tyr Pro Asp Arg Ser Lys
1115 1120 1125
Leu Tyr Thr Gly Asn Pro Ile Thr Ile Lys Ser Val Ser Asp Lys
1130 1135 1140
Asn Pro Tyr Ser Arg Ile Leu Asn Gly Asp Asn Ile Ile Leu His
1145 1150 1155
Met Leu Tyr Asn Ser Arg Lys Tyr Met Ile Ile Arg Asp Thr Asp
1160 1165 1170
Thr Ile Tyr Ala Thr Gln Gly Gly Glu Cys Ser Gln Asn Cys Val
1175 1180 1185
Tyr Ala Leu Lys Leu Gln Ser Asn Leu Gly Asn Tyr Gly Ile Gly
1190 1195 1200
Ile Phe Ser Ile Lys Asn Ile Val Ser Lys Asn Lys Tyr Cys Ser
1205 1210 1215
Gln Ile Phe Ser Ser Phe Arg Glu Asn Thr Met Leu Leu Ala Asp
1220 1225 1230
Ile Tyr Lys Pro Trp Arg Phe Ser Phe Lys Asn Ala Tyr Thr Pro
1235 1240 1245
Val Ala Val Thr Asn Tyr Glu Thr Lys Leu Leu Ser Thr Ser Ser
1250 1255 1260
Phe Trp Lys Phe Ile Ser Arg Asp Pro Gly Trp Val Glu
1265 1270 1275
<210> 5
<211> 1252
<212> PRT
<213> 肉毒杆菌(Clostridium botulinum)
<400> 5
Met Pro Lys Ile Asn Ser Phe Asn Tyr Asn Asp Pro Val Asn Asp Arg
1 5 10 15
Thr Ile Leu Tyr Ile Lys Pro Gly Gly Cys Gln Glu Phe Tyr Lys Ser
20 25 30
Phe Asn Ile Met Lys Asn Ile Trp Ile Ile Pro Glu Arg Asn Val Ile
35 40 45
Gly Thr Thr Pro Gln Asp Phe His Pro Pro Thr Ser Leu Lys Asn Gly
50 55 60
Asp Ser Ser Tyr Tyr Asp Pro Asn Tyr Leu Gln Ser Asp Glu Glu Lys
65 70 75 80
Asp Arg Phe Leu Lys Ile Val Thr Lys Ile Phe Asn Arg Ile Asn Asn
85 90 95
Asn Leu Ser Gly Gly Ile Leu Leu Glu Glu Leu Ser Lys Ala Asn Pro
100 105 110
Tyr Leu Gly Asn Asp Asn Thr Pro Asp Asn Gln Phe His Ile Gly Asp
115 120 125
Ala Ser Ala Val Glu Ile Lys Phe Ser Asn Gly Ser Gln Asp Ile Leu
130 135 140
Leu Pro Asn Val Ile Ile Met Gly Ala Glu Pro Asp Leu Phe Glu Thr
145 150 155 160
Asn Ser Ser Asn Ile Ser Leu Arg Asn Asn Tyr Met Pro Ser Asn His
165 170 175
Gly Phe Gly Ser Ile Ala Ile Val Thr Phe Ser Pro Glu Tyr Ser Phe
180 185 190
Arg Phe Asn Asp Asn Ser Met Asn Glu Phe Ile Gln Asp Pro Ala Leu
195 200 205
Thr Leu Met His Glu Leu Ile His Ser Leu His Gly Leu Tyr Gly Ala
210 215 220
Lys Gly Ile Thr Thr Lys Tyr Thr Ile Thr Gln Lys Gln Asn Pro Leu
225 230 235 240
Ile Thr Asn Ile Arg Gly Thr Asn Ile Glu Glu Phe Leu Thr Phe Gly
245 250 255
Gly Thr Asp Leu Asn Ile Ile Thr Ser Ala Gln Ser Asn Asp Ile Tyr
260 265 270
Thr Asn Leu Leu Ala Asp Tyr Lys Lys Ile Ala Ser Lys Leu Ser Lys
275 280 285
Val Gln Val Ser Asn Pro Leu Leu Asn Pro Tyr Lys Asp Val Phe Glu
290 295 300
Ala Lys Tyr Gly Leu Asp Lys Asp Ala Ser Gly Ile Tyr Ser Val Asn
305 310 315 320
Ile Asn Lys Phe Asn Asp Ile Phe Lys Lys Leu Tyr Ser Phe Thr Glu
325 330 335
Phe Asp Leu Ala Thr Lys Phe Gln Val Lys Cys Arg Gln Thr Tyr Ile
340 345 350
Gly Gln Tyr Lys Tyr Phe Lys Leu Ser Asn Leu Leu Asn Asp Ser Ile
355 360 365
Tyr Asn Ile Ser Glu Gly Tyr Asn Ile Asn Asn Leu Lys Val Asn Phe
370 375 380
Arg Gly Gln Asn Ala Asn Leu Asn Pro Arg Ile Ile Thr Pro Ile Thr
385 390 395 400
Gly Arg Gly Leu Val Lys Lys Ile Ile Arg Phe Cys Lys Asn Ile Val
405 410 415
Ser Val Lys Gly Ile Arg Lys Ser Ile Cys Ile Glu Ile Asn Asn Gly
420 425 430
Glu Leu Phe Phe Val Ala Ser Glu Asn Ser Tyr Asn Asp Asp Asn Ile
435 440 445
Asn Thr Pro Lys Glu Ile Asp Asp Thr Val Thr Ser Asn Asn Asn Tyr
450 455 460
Glu Asn Asp Leu Asp Gln Val Ile Leu Asn Phe Asn Ser Glu Ser Ala
465 470 475 480
Pro Gly Leu Ser Asp Glu Lys Leu Asn Leu Thr Ile Gln Asn Asp Ala
485 490 495
Tyr Ile Pro Lys Tyr Asp Ser Asn Gly Thr Ser Asp Ile Glu Gln His
500 505 510
Asp Val Asn Glu Leu Asn Val Phe Phe Tyr Leu Asp Ala Gln Lys Val
515 520 525
Pro Glu Gly Glu Asn Asn Val Asn Leu Thr Ser Ser Ile Asp Thr Ala
530 535 540
Leu Leu Glu Gln Pro Lys Ile Tyr Thr Phe Phe Ser Ser Glu Phe Ile
545 550 555 560
Asn Asn Val Asn Lys Pro Val Gln Ala Ala Leu Phe Val Ser Trp Ile
565 570 575
Gln Gln Val Leu Val Asp Phe Thr Thr Glu Ala Asn Gln Lys Ser Thr
580 585 590
Val Asp Lys Ile Ala Asp Ile Ser Ile Val Val Pro Tyr Ile Gly Leu
595 600 605
Ala Leu Asn Ile Gly Asn Glu Ala Gln Lys Gly Asn Phe Lys Asp Ala
610 615 620
Leu Glu Leu Leu Gly Ala Gly Ile Leu Leu Glu Phe Glu Pro Glu Leu
625 630 635 640
Leu Ile Pro Thr Ile Leu Val Phe Thr Ile Lys Ser Phe Leu Gly Ser
645 650 655
Ser Asp Asn Lys Asn Lys Val Ile Lys Ala Ile Asn Asn Ala Leu Lys
660 665 670
Glu Arg Asp Glu Lys Trp Lys Glu Val Tyr Ser Phe Ile Val Ser Asn
675 680 685
Trp Met Thr Lys Ile Asn Thr Gln Phe Asn Lys Arg Lys Glu Gln Met
690 695 700
Tyr Gln Ala Leu Gln Asn Gln Val Asn Ala Ile Lys Thr Ile Ile Glu
705 710 715 720
Ser Lys Tyr Asn Ser Tyr Thr Leu Glu Glu Lys Asn Glu Leu Thr Asn
725 730 735
Lys Tyr Asp Ile Lys Gln Ile Glu Asn Glu Leu Asn Gln Lys Val Ser
740 745 750
Ile Ala Met Asn Asn Ile Asp Arg Phe Leu Thr Glu Ser Ser Ile Ser
755 760 765
Tyr Leu Met Lys Leu Ile Asn Glu Val Lys Ile Asn Lys Leu Arg Glu
770 775 780
Tyr Asp Glu Asn Val Lys Thr Tyr Leu Leu Asn Tyr Ile Ile Gln His
785 790 795 800
Gly Ser Ile Leu Gly Glu Ser Gln Gln Glu Leu Asn Ser Met Val Thr
805 810 815
Asp Thr Leu Asn Asn Ser Ile Pro Phe Lys Leu Ser Ser Tyr Thr Asp
820 825 830
Asp Lys Ile Leu Ile Ser Tyr Phe Asn Lys Phe Phe Lys Arg Ile Lys
835 840 845
Ser Ser Ser Val Leu Asn Met Arg Tyr Lys Asn Asp Lys Tyr Val Asp
850 855 860
Thr Ser Gly Tyr Asp Ser Asn Ile Asn Ile Asn Gly Asp Val Tyr Lys
865 870 875 880
Tyr Pro Thr Asn Lys Asn Gln Phe Gly Ile Tyr Asn Asp Lys Leu Ser
885 890 895
Glu Val Asn Ile Ser Gln Asn Asp Tyr Ile Ile Tyr Asp Asn Lys Tyr
900 905 910
Lys Asn Phe Ser Ile Ser Phe Trp Val Arg Ile Pro Asn Tyr Asp Asn
915 920 925
Lys Ile Val Asn Val Asn Asn Glu Tyr Thr Ile Ile Asn Cys Met Arg
930 935 940
Asp Asn Asn Ser Gly Trp Lys Val Ser Leu Asn His Asn Glu Ile Ile
945 950 955 960
Trp Thr Leu Gln Asp Asn Ala Gly Ile Asn Gln Lys Leu Ala Phe Asn
965 970 975
Tyr Gly Asn Ala Asn Gly Ile Ser Asp Tyr Ile Asn Lys Trp Ile Phe
980 985 990
Val Thr Ile Thr Asn Asp Arg Leu Gly Asp Ser Lys Leu Tyr Ile Asn
995 1000 1005
Gly Asn Leu Ile Asp Gln Lys Ser Ile Leu Asn Leu Gly Asn Ile
1010 1015 1020
His Val Ser Asp Asn Ile Leu Phe Lys Ile Val Asn Cys Ser Tyr
1025 1030 1035
Thr Arg Tyr Ile Gly Ile Arg Tyr Phe Asn Ile Phe Asp Lys Glu
1040 1045 1050
Leu Asp Glu Thr Glu Ile Gln Thr Leu Tyr Ser Asn Glu Pro Asn
1055 1060 1065
Thr Asn Ile Leu Lys Asp Phe Trp Gly Asn Tyr Leu Leu Tyr Asp
1070 1075 1080
Lys Glu Tyr Tyr Leu Leu Asn Val Leu Lys Pro Asn Asn Phe Ile
1085 1090 1095
Asp Arg Arg Lys Asp Ser Thr Leu Ser Ile Asn Asn Ile Arg Ser
1100 1105 1110
Thr Ile Leu Leu Ala Asn Arg Leu Tyr Ser Gly Ile Lys Val Lys
1115 1120 1125
Ile Gln Arg Val Asn Asn Ser Ser Thr Asn Asp Asn Leu Val Arg
1130 1135 1140
Lys Asn Asp Gln Val Tyr Ile Asn Phe Val Ala Ser Lys Thr His
1145 1150 1155
Leu Phe Pro Leu Tyr Ala Asp Thr Ala Thr Thr Asn Lys Glu Lys
1160 1165 1170
Thr Ile Lys Ile Ser Ser Ser Gly Asn Arg Phe Asn Gln Val Val
1175 1180 1185
Val Met Asn Ser Val Gly Asn Asn Cys Thr Met Asn Phe Lys Asn
1190 1195 1200
Asn Asn Gly Asn Asn Ile Gly Leu Leu Gly Phe Lys Ala Asp Thr
1205 1210 1215
Val Val Ala Ser Thr Trp Tyr Tyr Thr His Met Arg Asp His Thr
1220 1225 1230
Asn Ser Asn Gly Cys Phe Trp Asn Phe Ile Ser Glu Glu His Gly
1235 1240 1245
Trp Gln Glu Lys
1250
<210> 6
<211> 1274
<212> PRT
<213> 肉毒杆菌(Clostridium botulinum)
<400> 6
Met Pro Val Ala Ile Asn Ser Phe Asn Tyr Asn Asp Pro Val Asn Asp
1 5 10 15
Asp Thr Ile Leu Tyr Met Gln Ile Pro Tyr Glu Glu Lys Ser Lys Lys
20 25 30
Tyr Tyr Lys Ala Phe Glu Ile Met Arg Asn Val Trp Ile Ile Pro Glu
35 40 45
Arg Asn Thr Ile Gly Thr Asn Pro Ser Asp Phe Asp Pro Pro Ala Ser
50 55 60
Leu Lys Asn Gly Ser Ser Ala Tyr Tyr Asp Pro Asn Tyr Leu Thr Thr
65 70 75 80
Asp Ala Glu Lys Asp Arg Tyr Leu Lys Thr Thr Ile Lys Leu Phe Lys
85 90 95
Arg Ile Asn Ser Asn Pro Ala Gly Lys Val Leu Leu Gln Glu Ile Ser
100 105 110
Tyr Ala Lys Pro Tyr Leu Gly Asn Asp His Thr Pro Ile Asp Glu Phe
115 120 125
Ser Pro Val Thr Arg Thr Thr Ser Val Asn Ile Lys Leu Ser Thr Asn
130 135 140
Val Glu Ser Ser Met Leu Leu Asn Leu Leu Val Leu Gly Ala Gly Pro
145 150 155 160
Asp Ile Phe Glu Ser Cys Cys Tyr Pro Val Arg Lys Leu Ile Asp Pro
165 170 175
Asp Val Val Tyr Asp Pro Ser Asn Tyr Gly Phe Gly Ser Ile Asn Ile
180 185 190
Val Thr Phe Ser Pro Glu Tyr Glu Tyr Thr Phe Asn Asp Ile Ser Gly
195 200 205
Gly His Asn Ser Ser Thr Glu Ser Phe Ile Ala Asp Pro Ala Ile Ser
210 215 220
Leu Ala His Glu Leu Ile His Ala Leu His Gly Leu Tyr Gly Ala Arg
225 230 235 240
Gly Val Thr Tyr Glu Glu Thr Ile Glu Val Lys Gln Ala Pro Leu Met
245 250 255
Ile Ala Glu Lys Pro Ile Arg Leu Glu Glu Phe Leu Thr Phe Gly Gly
260 265 270
Gln Asp Leu Asn Ile Ile Thr Ser Ala Met Lys Glu Lys Ile Tyr Asn
275 280 285
Asn Leu Leu Ala Asn Tyr Glu Lys Ile Ala Thr Arg Leu Ser Glu Val
290 295 300
Asn Ser Ala Pro Pro Glu Tyr Asp Ile Asn Glu Tyr Lys Asp Tyr Phe
305 310 315 320
Gln Trp Lys Tyr Gly Leu Asp Lys Asn Ala Asp Gly Ser Tyr Thr Val
325 330 335
Asn Glu Asn Lys Phe Asn Glu Ile Tyr Lys Lys Leu Tyr Ser Phe Thr
340 345 350
Glu Ser Asp Leu Ala Asn Lys Phe Lys Val Lys Cys Arg Asn Thr Tyr
355 360 365
Phe Ile Lys Tyr Glu Phe Leu Lys Val Pro Asn Leu Leu Asp Asp Asp
370 375 380
Ile Tyr Thr Val Ser Glu Gly Phe Asn Ile Gly Asn Leu Ala Val Asn
385 390 395 400
Asn Arg Gly Gln Ser Ile Lys Leu Asn Pro Lys Ile Ile Asp Ser Ile
405 410 415
Pro Asp Lys Gly Leu Val Glu Lys Ile Val Lys Phe Cys Lys Ser Val
420 425 430
Ile Pro Arg Lys Gly Thr Lys Ala Pro Pro Arg Leu Cys Ile Arg Val
435 440 445
Asn Asn Ser Glu Leu Phe Phe Val Ala Ser Glu Ser Ser Tyr Asn Glu
450 455 460
Asn Asp Ile Asn Thr Pro Lys Glu Ile Asp Asp Thr Thr Asn Leu Asn
465 470 475 480
Asn Asn Tyr Arg Asn Asn Leu Asp Glu Val Ile Leu Asp Tyr Asn Ser
485 490 495
Gln Thr Ile Pro Gln Ile Ser Asn Arg Thr Leu Asn Thr Leu Val Gln
500 505 510
Asp Asn Ser Tyr Val Pro Arg Tyr Asp Ser Asn Gly Thr Ser Glu Ile
515 520 525
Glu Glu Tyr Asp Val Val Asp Phe Asn Val Phe Phe Tyr Leu His Ala
530 535 540
Gln Lys Val Pro Glu Gly Glu Thr Asn Ile Ser Leu Thr Ser Ser Ile
545 550 555 560
Asp Thr Ala Leu Leu Glu Glu Ser Lys Asp Ile Phe Phe Ser Ser Glu
565 570 575
Phe Ile Asp Thr Ile Asn Lys Pro Val Asn Ala Ala Leu Phe Ile Asp
580 585 590
Trp Ile Ser Lys Val Ile Arg Asp Phe Thr Thr Glu Ala Thr Gln Lys
595 600 605
Ser Thr Val Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Val
610 615 620
Gly Leu Ala Leu Asn Ile Ile Ile Glu Ala Glu Lys Gly Asn Phe Glu
625 630 635 640
Glu Ala Phe Glu Leu Leu Gly Val Gly Ile Leu Leu Glu Phe Val Pro
645 650 655
Glu Leu Thr Ile Pro Val Ile Leu Val Phe Thr Ile Lys Ser Tyr Ile
660 665 670
Asp Ser Tyr Glu Asn Lys Asn Lys Ala Ile Lys Ala Ile Asn Asn Ser
675 680 685
Leu Ile Glu Arg Glu Ala Lys Trp Lys Glu Ile Tyr Ser Trp Ile Val
690 695 700
Ser Asn Trp Leu Thr Arg Ile Asn Thr Gln Phe Asn Lys Arg Lys Glu
705 710 715 720
Gln Met Tyr Gln Ala Leu Gln Asn Gln Val Asp Ala Ile Lys Thr Ala
725 730 735
Ile Glu Tyr Lys Tyr Asn Asn Tyr Thr Ser Asp Glu Lys Asn Arg Leu
740 745 750
Glu Ser Glu Tyr Asn Ile Asn Asn Ile Glu Glu Glu Leu Asn Lys Lys
755 760 765
Val Ser Leu Ala Met Lys Asn Ile Glu Arg Phe Met Thr Glu Ser Ser
770 775 780
Ile Ser Tyr Leu Met Lys Leu Ile Asn Glu Ala Lys Val Gly Lys Leu
785 790 795 800
Lys Lys Tyr Asp Asn His Val Lys Ser Asp Leu Leu Asn Tyr Ile Leu
805 810 815
Asp His Arg Ser Ile Leu Gly Glu Gln Thr Asn Glu Leu Ser Asp Leu
820 825 830
Val Thr Ser Thr Leu Asn Ser Ser Ile Pro Phe Glu Leu Ser Ser Tyr
835 840 845
Thr Asn Asp Lys Ile Leu Ile Ile Tyr Phe Asn Arg Leu Tyr Lys Lys
850 855 860
Ile Lys Asp Ser Ser Ile Leu Asp Met Arg Tyr Glu Asn Asn Lys Phe
865 870 875 880
Ile Asp Ile Ser Gly Tyr Gly Ser Asn Ile Ser Ile Asn Gly Asn Val
885 890 895
Tyr Ile Tyr Ser Thr Asn Arg Asn Gln Phe Gly Ile Tyr Asn Ser Arg
900 905 910
Leu Ser Glu Val Asn Ile Ala Gln Asn Asn Asp Ile Ile Tyr Asn Ser
915 920 925
Arg Tyr Gln Asn Phe Ser Ile Ser Phe Trp Val Arg Ile Pro Lys His
930 935 940
Tyr Lys Pro Met Asn His Asn Arg Glu Tyr Thr Ile Ile Asn Cys Met
945 950 955 960
Gly Asn Asn Asn Ser Gly Trp Lys Ile Ser Leu Arg Thr Val Arg Asp
965 970 975
Cys Glu Ile Ile Trp Thr Leu Gln Asp Thr Ser Gly Asn Lys Glu Asn
980 985 990
Leu Ile Phe Arg Tyr Glu Glu Leu Asn Arg Ile Ser Asn Tyr Ile Asn
995 1000 1005
Lys Trp Ile Phe Val Thr Ile Thr Asn Asn Arg Leu Gly Asn Ser
1010 1015 1020
Arg Ile Tyr Ile Asn Gly Asn Leu Ile Val Glu Lys Ser Ile Ser
1025 1030 1035
Asn Leu Gly Asp Ile His Val Ser Asp Asn Ile Leu Phe Lys Ile
1040 1045 1050
Val Gly Cys Asp Asp Glu Thr Tyr Val Gly Ile Arg Tyr Phe Lys
1055 1060 1065
Val Phe Asn Thr Glu Leu Asp Lys Thr Glu Ile Glu Thr Leu Tyr
1070 1075 1080
Ser Asn Glu Pro Asp Pro Ser Ile Leu Lys Asn Tyr Trp Gly Asn
1085 1090 1095
Tyr Leu Leu Tyr Asn Lys Lys Tyr Tyr Leu Phe Asn Leu Leu Arg
1100 1105 1110
Lys Asp Lys Tyr Ile Thr Leu Asn Ser Gly Ile Leu Asn Ile Asn
1115 1120 1125
Gln Gln Arg Gly Val Thr Glu Gly Ser Val Phe Leu Asn Tyr Lys
1130 1135 1140
Leu Tyr Glu Gly Val Glu Val Ile Ile Arg Lys Asn Gly Pro Ile
1145 1150 1155
Asp Ile Ser Asn Thr Asp Asn Phe Val Arg Lys Asn Asp Leu Ala
1160 1165 1170
Tyr Ile Asn Val Val Asp Arg Gly Val Glu Tyr Arg Leu Tyr Ala
1175 1180 1185
Asp Thr Lys Ser Glu Lys Glu Lys Ile Ile Arg Thr Ser Asn Leu
1190 1195 1200
Asn Asp Ser Leu Gly Gln Ile Ile Val Met Asp Ser Ile Gly Asn
1205 1210 1215
Asn Cys Thr Met Asn Phe Gln Asn Asn Asn Gly Ser Asn Ile Gly
1220 1225 1230
Leu Leu Gly Phe His Ser Asn Asn Leu Val Ala Ser Ser Trp Tyr
1235 1240 1245
Tyr Asn Asn Ile Arg Arg Asn Thr Ser Ser Asn Gly Cys Phe Trp
1250 1255 1260
Ser Ser Ile Ser Lys Glu Asn Gly Trp Lys Glu
1265 1270
<210> 7
<211> 1297
<212> PRT
<213> 肉毒杆菌(Clostridium botulinum)
<400> 7
Met Pro Val Asn Ile Lys Asn Phe Asn Tyr Asn Asp Pro Ile Asn Asn
1 5 10 15
Asp Asp Ile Ile Met Met Glu Pro Phe Asn Asp Pro Gly Pro Gly Thr
20 25 30
Tyr Tyr Lys Ala Phe Arg Ile Ile Asp Arg Ile Trp Ile Val Pro Glu
35 40 45
Arg Phe Thr Tyr Gly Phe Gln Pro Asp Gln Phe Asn Ala Ser Thr Gly
50 55 60
Val Phe Ser Lys Asp Val Tyr Glu Tyr Tyr Asp Pro Thr Tyr Leu Lys
65 70 75 80
Thr Asp Ala Glu Lys Asp Lys Phe Leu Lys Thr Met Ile Lys Leu Phe
85 90 95
Asn Arg Ile Asn Ser Lys Pro Ser Gly Gln Arg Leu Leu Asp Met Ile
100 105 110
Val Asp Ala Ile Pro Tyr Leu Gly Asn Ala Ser Thr Pro Pro Asp Lys
115 120 125
Phe Ala Ala Asn Val Ala Asn Val Ser Ile Asn Lys Lys Ile Ile Gln
130 135 140
Pro Gly Ala Glu Asp Gln Ile Lys Gly Leu Met Thr Asn Leu Ile Ile
145 150 155 160
Phe Gly Pro Gly Pro Val Leu Ser Asp Asn Phe Thr Asp Ser Met Ile
165 170 175
Met Asn Gly His Ser Pro Ile Ser Glu Gly Phe Gly Ala Arg Met Met
180 185 190
Ile Arg Phe Cys Pro Ser Cys Leu Asn Val Phe Asn Asn Val Gln Glu
195 200 205
Asn Lys Asp Thr Ser Ile Phe Ser Arg Arg Ala Tyr Phe Ala Asp Pro
210 215 220
Ala Leu Thr Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr
225 230 235 240
Gly Ile Lys Ile Ser Asn Leu Pro Ile Thr Pro Asn Thr Lys Glu Phe
245 250 255
Phe Met Gln His Ser Asp Pro Val Gln Ala Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly His Asp Pro Ser Val Ile Ser Pro Ser Thr Asp Met Asn Ile
275 280 285
Tyr Asn Lys Ala Leu Gln Asn Phe Gln Asp Ile Ala Asn Arg Leu Asn
290 295 300
Ile Val Ser Ser Ala Gln Gly Ser Gly Ile Asp Ile Ser Leu Tyr Lys
305 310 315 320
Gln Ile Tyr Lys Asn Lys Tyr Asp Phe Val Glu Asp Pro Asn Gly Lys
325 330 335
Tyr Ser Val Asp Lys Asp Lys Phe Asp Lys Leu Tyr Lys Ala Leu Met
340 345 350
Phe Gly Phe Thr Glu Thr Asn Leu Ala Gly Glu Tyr Gly Ile Lys Thr
355 360 365
Arg Tyr Ser Tyr Phe Ser Glu Tyr Leu Pro Pro Ile Lys Thr Glu Lys
370 375 380
Leu Leu Asp Asn Thr Ile Tyr Thr Gln Asn Glu Gly Phe Asn Ile Ala
385 390 395 400
Ser Lys Asn Leu Lys Thr Glu Phe Asn Gly Gln Asn Lys Ala Val Asn
405 410 415
Lys Glu Ala Tyr Glu Glu Ile Ser Leu Glu His Leu Val Ile Tyr Arg
420 425 430
Ile Ala Met Cys Lys Pro Val Met Tyr Lys Asn Thr Gly Lys Ser Glu
435 440 445
Gln Cys Ile Ile Val Asn Asn Glu Asp Leu Phe Phe Ile Ala Asn Lys
450 455 460
Asp Ser Phe Ser Lys Asp Leu Ala Lys Ala Glu Thr Ile Ala Tyr Asn
465 470 475 480
Thr Gln Asn Asn Thr Ile Glu Asn Asn Phe Ser Ile Asp Gln Leu Ile
485 490 495
Leu Asp Asn Asp Leu Ser Ser Gly Ile Asp Leu Pro Asn Glu Asn Thr
500 505 510
Glu Pro Phe Thr Asn Phe Asp Asp Ile Asp Ile Pro Val Tyr Ile Lys
515 520 525
Gln Ser Ala Leu Lys Lys Ile Phe Val Asp Gly Asp Ser Leu Phe Glu
530 535 540
Tyr Leu His Ala Gln Thr Phe Pro Ser Asn Ile Glu Asn Leu Gln Leu
545 550 555 560
Thr Asn Ser Leu Asn Asp Ala Leu Arg Asn Asn Asn Lys Val Tyr Thr
565 570 575
Phe Phe Ser Thr Asn Leu Val Glu Lys Ala Asn Thr Val Val Gly Ala
580 585 590
Ser Leu Phe Val Asn Trp Val Lys Gly Val Ile Asp Asp Phe Thr Ser
595 600 605
Glu Ser Thr Gln Lys Ser Thr Ile Asp Lys Val Ser Asp Val Ser Ile
610 615 620
Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Val Gly Asn Glu Thr Ala
625 630 635 640
Lys Glu Asn Phe Lys Asn Ala Phe Glu Ile Gly Gly Ala Ala Ile Leu
645 650 655
Met Glu Phe Ile Pro Glu Leu Ile Val Pro Ile Val Gly Phe Phe Thr
660 665 670
Leu Glu Ser Tyr Val Gly Asn Lys Gly His Ile Ile Met Thr Ile Ser
675 680 685
Asn Ala Leu Lys Lys Arg Asp Gln Lys Trp Thr Asp Met Tyr Gly Leu
690 695 700
Ile Val Ser Gln Trp Leu Ser Thr Val Asn Thr Gln Phe Tyr Thr Ile
705 710 715 720
Lys Glu Arg Met Tyr Asn Ala Leu Asn Asn Gln Ser Gln Ala Ile Glu
725 730 735
Lys Ile Ile Glu Asp Gln Tyr Asn Arg Tyr Ser Glu Glu Asp Lys Met
740 745 750
Asn Ile Asn Ile Asp Phe Asn Asp Ile Asp Phe Lys Leu Asn Gln Ser
755 760 765
Ile Asn Leu Ala Ile Asn Asn Ile Asp Asp Phe Ile Asn Gln Cys Ser
770 775 780
Ile Ser Tyr Leu Met Asn Arg Met Ile Pro Leu Ala Val Lys Lys Leu
785 790 795 800
Lys Asp Phe Asp Asp Asn Leu Lys Arg Asp Leu Leu Glu Tyr Ile Asp
805 810 815
Thr Asn Glu Leu Tyr Leu Leu Asp Glu Val Asn Ile Leu Lys Ser Lys
820 825 830
Val Asn Arg His Leu Lys Asp Ser Ile Pro Phe Asp Leu Ser Leu Tyr
835 840 845
Thr Lys Asp Thr Ile Leu Ile Gln Val Phe Asn Asn Tyr Ile Ser Asn
850 855 860
Ile Ser Ser Asn Ala Ile Leu Ser Leu Ser Tyr Arg Gly Gly Arg Leu
865 870 875 880
Ile Asp Ser Ser Gly Tyr Gly Ala Thr Met Asn Val Gly Ser Asp Val
885 890 895
Ile Phe Asn Asp Ile Gly Asn Gly Gln Phe Lys Leu Asn Asn Ser Glu
900 905 910
Asn Ser Asn Ile Thr Ala His Gln Ser Lys Phe Val Val Tyr Asp Ser
915 920 925
Met Phe Asp Asn Phe Ser Ile Asn Phe Trp Val Arg Thr Pro Lys Tyr
930 935 940
Asn Asn Asn Asp Ile Gln Thr Tyr Leu Gln Asn Glu Tyr Thr Ile Ile
945 950 955 960
Ser Cys Ile Lys Asn Asp Ser Gly Trp Lys Val Ser Ile Lys Gly Asn
965 970 975
Arg Ile Ile Trp Thr Leu Ile Asp Val Asn Ala Lys Ser Lys Ser Ile
980 985 990
Phe Phe Glu Tyr Ser Ile Lys Asp Asn Ile Ser Asp Tyr Ile Asn Lys
995 1000 1005
Trp Phe Ser Ile Thr Ile Thr Asn Asp Arg Leu Gly Asn Ala Asn
1010 1015 1020
Ile Tyr Ile Asn Gly Ser Leu Lys Lys Ser Glu Lys Ile Leu Asn
1025 1030 1035
Leu Asp Arg Ile Asn Ser Ser Asn Asp Ile Asp Phe Lys Leu Ile
1040 1045 1050
Asn Cys Thr Asp Thr Thr Lys Phe Val Trp Ile Lys Asp Phe Asn
1055 1060 1065
Ile Phe Gly Arg Glu Leu Asn Ala Thr Glu Val Ser Ser Leu Tyr
1070 1075 1080
Trp Ile Gln Ser Ser Thr Asn Thr Leu Lys Asp Phe Trp Gly Asn
1085 1090 1095
Pro Leu Arg Tyr Asp Thr Gln Tyr Tyr Leu Phe Asn Gln Gly Met
1100 1105 1110
Gln Asn Ile Tyr Ile Lys Tyr Phe Ser Lys Ala Ser Met Gly Glu
1115 1120 1125
Thr Ala Pro Arg Thr Asn Phe Asn Asn Ala Ala Ile Asn Tyr Gln
1130 1135 1140
Asn Leu Tyr Leu Gly Leu Arg Phe Ile Ile Lys Lys Ala Ser Asn
1145 1150 1155
Ser Arg Asn Ile Asn Asn Asp Asn Ile Val Arg Glu Gly Asp Tyr
1160 1165 1170
Ile Tyr Leu Asn Ile Asp Asn Ile Ser Asp Glu Ser Tyr Arg Val
1175 1180 1185
Tyr Val Leu Val Asn Ser Lys Glu Ile Gln Thr Gln Leu Phe Leu
1190 1195 1200
Ala Pro Ile Asn Asp Asp Pro Thr Phe Tyr Asp Val Leu Gln Ile
1205 1210 1215
Lys Lys Tyr Tyr Glu Lys Thr Thr Tyr Asn Cys Gln Ile Leu Cys
1220 1225 1230
Glu Lys Asp Thr Lys Thr Phe Gly Leu Phe Gly Ile Gly Lys Phe
1235 1240 1245
Val Lys Asp Tyr Gly Tyr Val Trp Asp Thr Tyr Asp Asn Tyr Phe
1250 1255 1260
Cys Ile Ser Gln Trp Tyr Leu Arg Arg Ile Ser Glu Asn Ile Asn
1265 1270 1275
Lys Leu Arg Leu Gly Cys Asn Trp Gln Phe Ile Pro Val Asp Glu
1280 1285 1290
Gly Trp Thr Glu
1295

Claims (18)

1.一种液体组合物,其包含蛋白质性神经毒素,表面活性剂,选自色氨酸和酪氨酸的氨基酸,包含钠、氯和磷酸根离子的缓冲剂,
其中所述液体组合物具有5.5至8的pH,
其中所述组合物不含动物来源的蛋白质,并且
其中所述液体组合物随时间稳定。
2.根据权利要求1所述的液体组合物,其中所述表面活性剂是非离子表面活性剂。
3.根据权利要求2所述的液体组合物,其中所述非离子表面活性剂是聚山梨醇酯,优选聚山梨醇酯20、聚山梨醇酯60或聚山梨醇酯80。
4.根据权利要求1-3任一项所述的液体组合物,其中所述氨基酸是色氨酸,优选L-色氨酸。
5.根据权利要求1-4任一项所述的液体组合物,其中所述缓冲剂还包含钾离子。
6.根据权利要求1-5任一项所述的液体组合物,其中所述组合物的pH为6.0-7.5。
7.根据权利要求1-6任一项所述的液体组合物,其中在5℃下在2、3、6、12、18、24或36个月时细胞外蛋白水解活性的损失不超过30%。
8.根据权利要求1-7任一项所述的液体组合物,其中所述蛋白质性神经毒素是肉毒杆菌神经毒素,其选自复合物形式的天然肉毒杆菌神经毒素、高纯度天然肉毒杆菌神经毒素和重组肉毒杆菌神经毒素。
9.根据权利要求8所述的液体组合物,其中所述肉毒杆菌神经毒素是选自肉毒杆菌神经毒素A、B、C、D、E、F或G,修饰的肉毒杆菌神经毒素和嵌合的肉毒杆菌神经毒素的重组肉毒杆菌神经毒素。
10.根据权利要求1-9任一项所述的液体组合物,其中所述液体组合物包含:
○每毫升4至10000个LD50单位的肉毒杆菌神经毒素,
○0.001至15%v/v聚山梨醇酯,
○0.1至5mg/mL色氨酸,
○10至500mM NaCl,
○1至50mM KCl,
○1至100mM磷酸钠,
pH为5.5至8,并且在5℃下稳定6个月。
11.根据权利要求10所述的液体组合物,其中所述液体组合物包含:
○每毫升10至2000个LD50单位的肉毒杆菌神经毒素,
○0.05至0.2%v/v聚山梨醇酯80,
○0.1至5mg/mL色氨酸,
○25至300mM NaCl,
○1至10mM KCl,
○2至50mM磷酸钠,
pH为6.0至7.5,并且在5℃下稳定12个月。
12.根据权利要求1-11任一项所述的液体组合物,其用于治疗。
13.根据权利要求12所述的液体组合物,其用于治疗或预防肌肉疾病、神经肌肉疾病、神经疾病、眼科疾病、疼痛疾病、心理疾病、关节疾病、炎性疾病、内分泌疾病或泌尿疾病。
14.根据权利要求1-11任一项所述的液体组合物在审美医学中的用途,例如用于治疗或预防皮肤皱纹,特别是面部皱纹,例如面部皱眉纹、眼部轮廓的皱纹、眉间皱眉纹、口角下垂、颈部皱纹(颈阔肌带)、下巴皱纹(颏肌纹、橘皮状皮肤、凹陷的下巴)、额头纹、“抓伤的皮肤”皱纹、鼻托处理或睡纹。
15.选自色氨酸和酪氨酸的氨基酸保护蛋白质性神经毒素免于在不含动物来源的蛋白质的液体组合物中降解的用途。
16.根据权利要求15所述的用途,其中所述氨基酸是色氨酸。
17.根据权利要求15或16所述的用途,其中所述蛋白质性神经毒素是肉毒杆菌神经毒素。
18.根据权利要求15所述的用途,其中所述氨基酸与表面活性剂和包含钠、氯和磷酸根离子的缓冲剂组合使用,并且所述液体组合物具有5.5至8的pH。
CN202010742639.2A 2016-05-27 2017-05-26 用色氨酸或酪氨酸稳定的液体神经毒素制剂 Active CN111701010B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010742639.2A CN111701010B (zh) 2016-05-27 2017-05-26 用色氨酸或酪氨酸稳定的液体神经毒素制剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2016062085 2016-05-27
EPPCT/EP2016/062085 2016-05-27
PCT/EP2017/062785 WO2017203038A1 (en) 2016-05-27 2017-05-26 Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
CN202010742639.2A CN111701010B (zh) 2016-05-27 2017-05-26 用色氨酸或酪氨酸稳定的液体神经毒素制剂
CN201780044565.1A CN109562148A (zh) 2016-05-27 2017-05-26 用色氨酸或酪氨酸稳定的液体神经毒素制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780044565.1A Division CN109562148A (zh) 2016-05-27 2017-05-26 用色氨酸或酪氨酸稳定的液体神经毒素制剂

Publications (2)

Publication Number Publication Date
CN111701010A true CN111701010A (zh) 2020-09-25
CN111701010B CN111701010B (zh) 2023-09-26

Family

ID=56289455

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010742639.2A Active CN111701010B (zh) 2016-05-27 2017-05-26 用色氨酸或酪氨酸稳定的液体神经毒素制剂
CN201780044565.1A Pending CN109562148A (zh) 2016-05-27 2017-05-26 用色氨酸或酪氨酸稳定的液体神经毒素制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780044565.1A Pending CN109562148A (zh) 2016-05-27 2017-05-26 用色氨酸或酪氨酸稳定的液体神经毒素制剂

Country Status (30)

Country Link
US (4) US20190183988A1 (zh)
EP (3) EP4026532A1 (zh)
JP (1) JP7053498B2 (zh)
KR (2) KR102399451B1 (zh)
CN (2) CN111701010B (zh)
AR (1) AR108631A1 (zh)
AU (1) AU2017270359B2 (zh)
BR (1) BR112018074311A2 (zh)
CA (1) CA3025437A1 (zh)
CY (2) CY1124237T1 (zh)
DK (2) DK3679946T3 (zh)
EA (1) EA038124B1 (zh)
ES (2) ES2911124T3 (zh)
GE (1) GEP20207139B (zh)
HR (2) HRP20220024T1 (zh)
HU (2) HUE057640T2 (zh)
IL (2) IL285190B (zh)
LT (2) LT3679946T (zh)
MX (1) MX2018014631A (zh)
PL (2) PL3463432T3 (zh)
PT (2) PT3463432T (zh)
RS (2) RS61340B1 (zh)
RU (1) RU2741497C9 (zh)
SA (1) SA518400513B1 (zh)
SG (1) SG11201810561YA (zh)
SI (2) SI3463432T1 (zh)
TW (1) TWI777955B (zh)
UA (1) UA123679C2 (zh)
WO (1) WO2017203038A1 (zh)
ZA (1) ZA201807904B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
SG10202100698QA (en) 2008-12-31 2021-02-25 Revance Therapeutics Inc Injectable Botulinum Toxin Formulations
IL268980B (en) 2009-06-25 2022-09-01 Revance Therapeutics Inc Botulinum toxin formulations without albumin
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
EP3436054B2 (en) 2016-09-13 2022-07-27 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
JP2021508453A (ja) * 2017-12-20 2021-03-11 アラーガン、インコーポレイテッドAllergan,Incorporated ボツリヌス毒素細胞結合ドメインポリペプチドおよび皮膚の若返りのための使用方法
TW202112348A (zh) * 2019-06-07 2021-04-01 英商益普生生物製藥有限公司 中度至極重度眉間紋及眼角外紋之治療
AU2023207838A1 (en) 2022-01-14 2024-07-04 Galderma Holding SA Treatment of moderate to very severe glabellar lines and lateral canthal lines
WO2023156389A1 (en) * 2022-02-15 2023-08-24 Merz Pharma Gmbh & Co. Kgaa Liquid botulinum toxin formulation and use thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909564A1 (en) * 1996-04-26 1999-04-21 Chugai Seiyaku Kabushiki Kaisha Erythropoietin solution preparation
US20030092622A1 (en) * 2000-02-29 2003-05-15 Yasushi Sato Preparation stabilized over long time
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
CN1616084A (zh) * 2000-02-08 2005-05-18 阿勒根公司 肉毒杆菌毒素药物组合物
WO2006013370A1 (en) * 2004-08-04 2006-02-09 Ipsen Limited Pharmaceutical composition containing botulinum neurotoxin a2
CN101687046A (zh) * 2007-07-10 2010-03-31 株式会社美地拓斯 稳定性改善的肉毒毒素药物液体组合物
CN102327602A (zh) * 2004-07-12 2012-01-25 伊普森生物制药有限公司 包含肉毒、非离子型表面活性剂、氯化钠和蔗糖的药物组合物
WO2015166242A1 (en) * 2014-04-29 2015-11-05 Ipsen Bioinnovation Limited Manufacture of recombinant clostridium botulinum neurotoxins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US6627602B2 (en) * 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
EP2266600B1 (en) * 2004-07-26 2014-09-10 Merz Pharma GmbH & Co. KGaA Therapeutic composition with a botulinum neurotoxin
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR101910490B1 (ko) 2011-06-01 2018-10-22 바이오메디슨, 인코퍼레이티드 비-fret 보툴리눔 검정법
KR101640694B1 (ko) 2011-09-29 2016-07-18 셀스냅, 엘엘씨 독소생산능 시험용 조성물 및 방법
KR101357999B1 (ko) * 2012-03-20 2014-02-03 함종욱 보툴리눔 에이형 독소의 액상제품
EP3052120A1 (en) 2013-09-30 2016-08-10 Galderma S.A. Prostate cancer treatment

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909564A1 (en) * 1996-04-26 1999-04-21 Chugai Seiyaku Kabushiki Kaisha Erythropoietin solution preparation
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
CN1616084A (zh) * 2000-02-08 2005-05-18 阿勒根公司 肉毒杆菌毒素药物组合物
US20030092622A1 (en) * 2000-02-29 2003-05-15 Yasushi Sato Preparation stabilized over long time
CN102327602A (zh) * 2004-07-12 2012-01-25 伊普森生物制药有限公司 包含肉毒、非离子型表面活性剂、氯化钠和蔗糖的药物组合物
WO2006013370A1 (en) * 2004-08-04 2006-02-09 Ipsen Limited Pharmaceutical composition containing botulinum neurotoxin a2
CN101687046A (zh) * 2007-07-10 2010-03-31 株式会社美地拓斯 稳定性改善的肉毒毒素药物液体组合物
WO2015166242A1 (en) * 2014-04-29 2015-11-05 Ipsen Bioinnovation Limited Manufacture of recombinant clostridium botulinum neurotoxins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D DRESSLER: "Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins" *
梁筱等: "A 型肉毒毒素用于注射美容的并发症及其防治措施" *

Also Published As

Publication number Publication date
HRP20202070T1 (hr) 2021-02-19
HUE052023T2 (hu) 2021-04-28
HRP20220024T1 (hr) 2022-04-01
JP7053498B2 (ja) 2022-04-12
US20210330765A1 (en) 2021-10-28
GEP20207139B (en) 2020-07-27
DK3679946T3 (da) 2022-02-07
US20190183988A1 (en) 2019-06-20
IL263173B (en) 2021-08-31
PT3679946T (pt) 2022-01-14
CN111701010B (zh) 2023-09-26
IL285190B (en) 2022-07-01
EP3463432A1 (en) 2019-04-10
KR20190022548A (ko) 2019-03-06
EP4026532A1 (en) 2022-07-13
IL285190A (en) 2021-08-31
SA518400513B1 (ar) 2022-11-03
BR112018074311A2 (pt) 2019-10-01
KR20220054887A (ko) 2022-05-03
PT3463432T (pt) 2021-01-12
CY1124916T1 (el) 2023-01-05
SI3463432T1 (sl) 2021-02-26
PL3679946T3 (pl) 2022-05-30
LT3679946T (lt) 2022-02-10
HUE057640T2 (hu) 2022-05-28
SG11201810561YA (en) 2018-12-28
CN109562148A (zh) 2019-04-02
KR102399451B1 (ko) 2022-05-23
AU2017270359B2 (en) 2023-09-21
SI3679946T1 (sl) 2022-04-29
EA038124B1 (ru) 2021-07-09
WO2017203038A1 (en) 2017-11-30
AR108631A1 (es) 2018-09-12
CY1124237T1 (el) 2022-07-22
RU2018142149A (ru) 2020-06-29
IL263173A (en) 2018-12-31
US20240050539A1 (en) 2024-02-15
TWI777955B (zh) 2022-09-21
CA3025437A1 (en) 2017-11-30
JP2019517481A (ja) 2019-06-24
EP3463432B1 (en) 2020-10-07
MX2018014631A (es) 2019-06-12
EA201892493A1 (ru) 2019-04-30
RU2741497C9 (ru) 2021-04-30
RU2741497C2 (ru) 2021-01-26
RU2018142149A3 (zh) 2020-07-23
EP3679946B1 (en) 2022-01-05
ZA201807904B (en) 2020-05-27
ES2846350T3 (es) 2021-07-28
US20230181702A1 (en) 2023-06-15
EP3679946A1 (en) 2020-07-15
LT3463432T (lt) 2021-01-25
AU2017270359A1 (en) 2018-12-13
RS61340B1 (sr) 2021-02-26
RS62832B1 (sr) 2022-02-28
US20230190892A9 (en) 2023-06-22
UA123679C2 (uk) 2021-05-12
ES2911124T3 (es) 2022-05-17
TW201742632A (zh) 2017-12-16
KR102423739B1 (ko) 2022-07-21
PL3463432T3 (pl) 2021-04-19
DK3463432T3 (da) 2021-01-04

Similar Documents

Publication Publication Date Title
CN111701010B (zh) 用色氨酸或酪氨酸稳定的液体神经毒素制剂
US10561604B2 (en) Pharmaceutical composition comprising botulinum, a non ionic surfactant, sodium chloride and sucrose
US20220160844A1 (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
NZ788585A (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
GB2418358A (en) Pharmaceutical composition comprising botulinum neurotoxin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029295

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant